

2020 ANNUAL REPORT HIGHLIGHTS

Transformative Care in Unprecedented Times

 **NorthShore**
University HealthSystem

Kellogg Cancer Center



Our 2020 Annual Report showcases highlights of our clinical and research efforts. To learn more about our full range of programs and services, please visit northshore.org/cancer.

At NorthShore University HealthSystem (NorthShore) Kellogg Cancer Center, our collaborative teams of physicians, nurses and other specially trained clinicians are dedicated to providing the highest level of personalized care to each patient.

Like healthcare institutions across the country, we faced new and significant challenges this year brought on by the pandemic. But our group of committed and compassionate caregivers worked to maintain a sense of normalcy while adopting new practices to maintain patient and staff safety. We have focused on minimizing risk of exposure for patients and staff while still offering essential care to improve patient outcomes.

We continue to leverage our strengths with our advanced molecular pathology and diagnostics laboratory capabilities, and we're developing a comprehensive immunotherapy program to ensure that our patients benefit from the latest technology and sophisticated treatment options.

As NorthShore has become a national leader in the integration of complex genomic information into clinical care, we're now establishing a groundbreaking program to incorporate the latest in genomic testing and science for our advanced cancer patients. The Kellogg Cancer Genomic Initiative reflects our commitment to personalized medicine and superior care.

Our academic affiliation with the University of Chicago Pritzker School of Medicine enables us to help train the next generation of physician leaders and brings benefits to patients through shared clinical and research initiatives.

NorthShore is certified by the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) as a premier medical



Dr. Bruce Brockstein



Dr. David J. Winchester

provider for practicing the highest standards of quality cancer care. NorthShore is recognized in *U.S. News & World Report's* Best Hospitals Survey as the #3 Hospital in Chicagoland and the state of Illinois. We are of course proud of these and other accomplishments, but we're most grateful for positive patient outcomes.

We offer our sincere thanks and gratitude to our donors. Charitable contributions are essential to our ongoing research and patient support programs, and we are especially honored by the generosity of so many patients and their families.



We remain committed to advancing efforts to prevent, diagnose and treat even the most complex cancers. We invite you to learn more about our team's shared mission to provide transformative care through the highlights in this report.

Bruce Brockstein, MD

Medical Director, NorthShore Kellogg Cancer Center,
Head, Division of Hematology/Oncology,
Kellogg-Scanlon Chair of Oncology

David J. Winchester, MD

Chairman, NorthShore Cancer Committee,
Associate Director for Surgical Specialties,
NorthShore Kellogg Cancer Center
Board of Directors, David P. Winchester, MD,
Chair of Surgical Oncology



Oncologists (from left) Dr. Javed Imam, Dr. Jeffrey Cilley and Dr. Elyse Lambiase provide care for patients at Swedish Hospital.

We are pleased to welcome our new colleagues at Swedish Hospital and look forward to ongoing collaboration in clinical and research initiatives aimed at advancing prevention, diagnosis and improved cancer treatment for all our patients.

Swedish Hospital

Part of **NorthShore**

Cancer Care During a Pandemic

Delivering lifesaving cancer care in the face of the COVID-19 pandemic required important adaptations and flexibility for the entire Kellogg Cancer Center team. New workflows and practices were quickly put in place to limit exposure and protect both patients and staff.

Patients were screened with calls before visits to the Kellogg Cancer Center, and clinical spaces were decompressed with some staff working from home and empty exam rooms used for staff nurses and treatment.

A no-visitor policy was implemented—and while initially very difficult for patients, it was ultimately well received as patients and families understood the importance of protecting their safety and limiting exposure to the virus.

Patients were individually assessed to determine the need for ongoing/immediate treatment versus the risks associated with potential exposure in a clinic visit as well as the risk of chemotherapy or radiation treatment for patients with COVID-19.

When possible, physician visits were conducted via telehealth and video calls with expanded virtual education efforts from the Kellogg Cancer Center nursing team. Video visits also enabled family members to be “present” and involved in their loved one’s care.

An education video was developed to help patients safely disconnect infusion pumps at home, and many other services—including simple injections and prescription pick-ups—were offered as a drive-thru option. Blood draws and lab work were done the day before treatment to minimize wait time at the cancer center.

Bolstering staff resilience was another important element of care during the pandemic. Regular staff well-being check-ins were initiated, and stress management techniques were offered by licensed clinical social workers. “Breathe” sessions became part of staff meetings, and Kellogg Cancer Center leadership and many grateful patients and families provided countless lunches and healthy snacks for physicians, nurses and the entire Kellogg Cancer Center team.

Elective operations and many cancer screening procedures were put on hold or canceled, creating another major challenge for oncology caregivers and patients. Various algorithms were used to weigh the risk of treatment with delaying treatment for individual patients. To optimize the care of patients when operations had to be delayed, hormone therapy or sometimes chemotherapy was used to bridge the gap until surgery could be safely performed.

While ongoing research and COVID-19-related studies were a challenge, most clinical trials and studies continued throughout the pandemic, with the emphasis on therapeutic interventions that show the greatest promise for patients.

As the Kellogg Cancer Center multidisciplinary team continues to rise to the many challenges associated with COVID-19, some of the new COVID-initiated processes are now being implemented long term, leveraging the learning from the pandemic. Collectively, the Kellogg Cancer Center team learned how to implement and adapt novel processes efficiently and effectively, remaining dedicated to patient safety and best outcomes.

Medical Oncology continues to see 85% of cancer patients in person and is operating at 95% of pre-COVID capacity, with extra safety precautions in place.



Kellogg Cancer Center nurse Lenore Krukowski draws blood for a patient's lab work. Rigorous safety procedures are in place to ensure the health and wellbeing of patients and staff.

One of the most important initiatives was developed by Kellogg Cancer Center Medical Director Bruce Brockstein, MD.

Just hours after the governor announced the stay-at-home order in March, Dr. Brockstein pulled together a coalition of Chicago-area leaders in cancer care to meet virtually and brainstorm best practices to keep patients and staff safe while also optimizing cancer-related outcomes.

The “C5” (Chicago Cancer Center COVID-19 Coalition) met through tele- or videoconference on Sunday mornings—and when necessary, by email. They continue to communicate collaboratively sharing important advances, data and advice to best serve patients in the

Metropolitan Chicago area. C5 participants are from large academic medical centers and large hospital based community practices, including Advocate Aurora Health, Edwards-Elmhurst Health, Loyola University Medical Center, Northwestern Medicine, Rush University Medical Center, The University of Chicago Medicine and The University of Illinois joined NorthShore in C5.

The spirit of collaboration was celebrated by Dr. Brockstein and his colleagues who continue to use the group resource as the pandemic persists.

In collaboration with the Mark R. Neaman Center for Personalized Medicine, Kellogg Cancer Center is now developing a groundbreaking program to incorporate the latest in genomic testing for patients diagnosed with cancer.



Kellogg Cancer Genomic Initiative

Novel testing and sophisticated programs like our Pharmacogenomics Clinic and Genomic Health Initiative (GHI) have helped establish NorthShore as a leader in the integration of complex genomic information into ongoing clinical care. In collaboration with the Neaman Center for Personalized Medicine, Kellogg Cancer Center is now developing a groundbreaking program to incorporate the latest in genomic testing for patients diagnosed with cancer.

The Kellogg Cancer Genomic Initiative (KCGI) uses next-generation sequencing to characterize tumor mutations for each new Kellogg patient with advanced or metastatic cancers where tumor genomics may help determine the best course of therapy. This advanced genetic testing of tumors identifies precise markers for more targeted therapies. The genomic data is used to both refine diagnoses and

identify molecular targets for specific treatments.

At the same time, pharmacogenomic assessment for new cancer patients contributes to a more advanced understanding of the appropriate therapeutic drugs and doses for each individual patient.

An initial pilot study of 500 Kellogg Cancer Center patients representing multiple tumor and disease types will begin in 2021, as COVID-19 delayed its planned start in 2020. Data from this critical study will be used to fully integrate genomics into a new routine standard of care for cancer patients.

Additional outcomes research projects, expanded testing and more complete analysis of liquid biopsy testing for patients whose metastases cannot be biopsied are all part of KCGI future initiatives.

Harnessing the Power of Immunotherapy

The last decade has brought enormous progress in the fight against cancer, and immunotherapy has been at the forefront. Immunotherapy drugs harness the power of the body's own immune system to identify and eradicate cancer cells.


While expert physicians at NorthShore have leveraged the power of immunotherapy for nearly a decade, the Kellogg Cancer Center is establishing a premier immunotherapy program ensuring maximum benefits for our patients in this rapidly evolving sphere.

Immunotherapy has had a positive impact on a growing majority of cancers including lung, melanoma, head and neck, genitourinary and specific blood cancers. One form of immunotherapy—CAR T, which involves extracting disease-fighting T cells from the patient's body, reengineering in a lab and then infusing back into the body—has been especially effective with leukemia. CAR T is very expensive, but demonstrated results have led to more private insurance companies and Medicare covering its use. While its use has been largely relegated to a few specialized university-based centers, we aim to incorporate these and similar therapies as they move into community-based cancer centers.

The extreme costs of many immunotherapy treatments have made Kellogg Cancer Center's patient financial advocates critical members of care teams as they work to secure coverage or industry donations for patients. Kellogg Cancer Center nurses, pharmacy teams and more have been specially trained in the complex therapies.

Immunotherapy efforts at NorthShore have been led by Kellogg Cancer Center Medical Director Bruce Brockstein, MD, and Thoracic Oncology Co-Director Thomas Hensing, MD, MS. By the end of 2021, close to a third of Kellogg Cancer Center patients will be treated with immunotherapy. And research, often in collaboration with major cancer centers and leading physician scientists across the country, continues to be an important part of the program to ensure that patients have access to life-changing and lifesaving therapies. Today, more than a third of Kellogg Cancer Center's clinical research activities are immunotherapy-focused.

Immunotherapy Total Number of Patient and Doses



Advancing Vital Research

Innovative research continues to drive improvements in clinical care and outcomes for patients at Kellogg Cancer Center. NorthShore patients have access to a broad range of clinical trials and potentially lifesaving treatments. As immunotherapy remains a growing source of optimism in the battle against cancer, research is particularly crucial in optimizing the evolving field of treatment.

Oncologist Thomas Hensing, MD, MS, was the principal investigator for the NorthShore-led multisite national trial that evaluated the sequencing of immunotherapy medication and standard chemotherapy in patients with metastatic non-small cell lung cancer.

"One of the key challenges in this patient population has been deciding who will most benefit from immunotherapy and whether

it should be combined with traditional chemotherapy," explained Dr. Hensing. Findings from the study have proved beneficial for patients at NorthShore and beyond.

Further insights related to the specific biology of individual patient tumors have also helped improve our cancer care, said Dr. Hensing, who presented results of the study at the American Society of Clinical Oncology international conference and expects to expand the findings with further research. Oncologist Nicholas Campbell, MD, helped enroll many of the patients involved in the study and continues to champion clinical research as a way to provide the best possible care for Kellogg Cancer Center patients.



Multidisciplinary Team Supports New Studies

Dr. Hensing (pictured left) leads NorthShore's COVID-19 Clinical Trials Scientific Review Committee, which has followed the paradigm established with our clinical research in oncology—namely, focusing on the studies that will best benefit patients today.

In addition to oncology, the multidisciplinary group includes representation from infectious disease, pulmonary care, intensive care, hospitalists and more. "We've been able to leverage our experience at Kellogg where we've developed a very effective way for our patients to quickly have access to important trials," said Dr. Hensing.

Lifesaving Treatments Keep Him in the Game

John Medel, like so many cancer patients, had a rough go with chemotherapy to treat sarcoma that had spread from his arm to his back and other areas. "I felt sorry for my wife; I was never in a good mood," recalled the 69-year-old active sports fan.

While the chemotherapy initially stopped the rare cancer's growth, it began growing again when the treatment was completed. Fortunately, Medel has joined the growing number of patients who are successfully treated with immunotherapy drugs that have not only kept his cancer at bay, but have come with minimal to no side effects.

"I've been very, very lucky," said Medel who receives regular infusions at the NorthShore Highland Park Hospital Kellogg Cancer Center for nearly two years and is cared for by oncologist and Kellogg-Scanlon Chair of Oncology Bruce Brockstein, MD.

Medel was referred to Dr. Brockstein from University of Chicago Medicine orthopaedic oncologist Rex Haydon, MD. "We thought very highly of him, and he spoke very highly of Dr. Brockstein," said Medel. "There was no doubt that I was with the right doctor."

"Immunotherapy is providing lots of new options for treatment, and in many cases helping us cure patients or give them many years of quality life," said Dr. Brockstein. "In the past, sometimes our only option was to give chemotherapy as a palliative treatment or in hopes of buying some time."

"It's gratifying to see patients like John doing so well and able to live life to the fullest," said Dr. Brockstein, who is impressed by Medel's drive. "It's been great to see him doing so well and tolerating treatment so well that we can concentrate much of our time together

on important things like curing the flaws of Chicago sports teams."

An avid bowler, Medel had to teach himself to bowl with his left hand following surgery to remove the first tumor in his arm. He also taught himself to pitch with his left hand and hopes someday to coach his grandson's Little League team.

Medel has high praise for the entire Kellogg Cancer Center team and is also grateful for help he received in securing his treatment drugs from the pharmaceutical company after being denied by his insurance.

Patient Financial Advocate Kendall Ward works with patients like Medel and has the critical role of coordinating efforts with insurance companies and manufacturers to ensure that patients get the right treatment without delay.

"It's really a joy—I get to call patients and give them good news," said Ward. "It's a blessing to be part of the Kellogg team, and I enjoy working with patients and knowing that they can focus on getting better without worrying about the financial aspects of care."



Patient Financial Advocate Kendall Ward

Advanced Surgical Expertise

Kellogg Cancer Center patients benefit from multidisciplinary teams of experts, including fellowship-trained surgeons performing the most sophisticated and minimally invasive techniques. Endoscopic submucosal dissection (ESD) is an advanced organ-sparing surgical procedure to remove gastrointestinal tumors or precancerous lesions in the esophagus, stomach or colon. This surgical procedure is currently being performed by NorthShore's Monika Krezalek, MD, and Louis W. Biegler Chair of Surgery Michael Ujiki, MD.

Leading-Edge Training

Our team of talented surgeons continues to have a national and international reach through development of and refinement of novel applications of minimally invasive surgery and natural orifice procedures. The Grainger Center for Simulation and Innovation (GCSI) is a state-of-the-art facility that enables advanced training for our team as well as surgeons from around the country and world who are drawn to the world-class resource and faculty.

Mindfulness Interventions

Surgical Oncology Division Head Katharine Yao, MD, is dedicated to transforming breast cancer care—and in addition to her efforts focused on women at high risk for the disease, she's now leading a novel mindfulness study. Dr. Yao and her team have worked to help patients make the best care decisions, including surgery, when faced with a diagnosis. She is now taking next steps to provide patients and their families mindfulness resources to help them make the best individual choice, hoping to help alleviate overwhelming anxiety and fear that often accompanies the stressful journey and often makes it difficult to understand treatment plans.

The study in partnership with Northwestern University Associate Professor of Medical Social Sciences and mindfulness expert David Victorson, PhD, includes development of mindfulness videos tailored to newly diagnosed patients, those currently undergoing treatment and survivors. All address overcoming and coping with cancer. Dr. Yao will study the impact of the mindfulness intervention on overall patient emotional well-being, anxiety and stress biomarkers.

The study is funded in part by a grant from the John Wayne Cancer Foundation and the Myra Rubenstein Weis Foundation.

Defeating Cancer with Genetic Testing

When Sandra McPherson decided to take advantage of the DNA-10K test offered by NorthShore, she looked forward to finding out about her ancestry. She never expected to learn that she carried a genetic mutation that put her at higher risk for breast and ovarian cancer.

Her first instinct was to ignore the results and the fact that she had the BRCA2 mutation, but her 24-year-old daughter Ali Oliveros insisted she take action. Following meetings with a genetic counselor and medical oncologist Allison DePersia, MD, who specializes in caring for high-risk patients with genetic mutations, McPherson quickly decided to undergo a bilateral mastectomy and a hysterectomy to dramatically reduce her risk of developing cancer.



Dr. Allison DePersia

Dr. DePersia walked McPherson, a fourth grade teacher and mother of three, through the options including increased mammography screening and surveillance or preemptive surgery. "While there are clear guidelines that take into account other factors, including a patient's age and family history, it's also a very personal decision," noted Dr. DePersia.

On the other side of both successful operations at NorthShore, 49-year-old McPherson is grateful for the lifesaving information and the opportunity to secure her future. "With surgery, I don't have to worry about getting cancer," said McPherson. "I'm a proactive person. If there's a problem, I find the solution."

Dr. DePersia suggested that Oliveros also consider genetic testing. While Oliveros knew her odds, she admitted it was still a bit of a shock to learn that she has the BRCA2 mutation. "I was hoping for better results, but I'm glad to know and can do



Personalized Medicine patient Sandra McPherson

something about it," she said. Dr. DePersia said Oliveros is young enough to follow guidelines for annual MRIs and breast exams every six months for now.

One of seven children born and raised in Colombia, South America, McPherson shared her DNA results with her siblings in the hope they, too, will consider genetic testing.

This knowledge is powerful," she said. "I try to live in the moment, but I need to do what I can to protect my future and my family's future."

Compassionate, Comprehensive Support for Patients



Advanced Nurse Practitioner Anisha Patel and Dr. Carol Rosenberg help cancer survivors with customized survivorship care plans, ongoing education and more, enabling them to thrive beyond their treatment.

Cancer patients and their families need more than expert diagnosis and treatment of their disease. At NorthShore, a full range of support services help patients throughout their cancer journey. From social workers to specially trained dietitians and patient financial advocates to an entire Integrative Medicine team, Kellogg Cancer Center offers a comprehensive array of programs to help patients heal and thrive during and after treatment. Specialized oncology nurses are a critical element of Kellogg Cancer Center's ability to provide compassionate care.

Our Myra Rubenstein Weis (MRW) Living in the Future (LIFE) Cancer Survivorship Program helps ensure the long-term health and quality of life for cancer survivors.

Psychosocial Support

Kellogg Cancer Center's Psychosocial Oncology Program provides services to help patients and their families navigate a myriad of emotional and practical needs brought on by a cancer diagnosis. The COVID-19 pandemic created further challenges for many cancer patients, and the psychosocial team worked tirelessly to provide additional support. Patients struggled with increased financial challenges, emotional isolation (including being alone for treatments due to necessary visitor restrictions at Kellogg Cancer Center), parenting, and anxiety due to COVID-19 vulnerability.

A middle-aged male patient with non-Hodgkin's lymphoma who lost his job during the COVID-19 pandemic was one of the patients to benefit from the team's additional support. Patient financial advocate Marissa Wiley was able to help the patient secure help with his hospital bills while the team also secured him a patient grant to help with expenses, all of which reduced his anxiety and led him to express his gratitude for all the support he received.

An elderly, lower income female patient with B-cell acute lymphoblastic leukemia was connected to reliable transportation to treatment and to the North Shore Senior Center for additional help at home. Anxious at treatment without the support of her husband who was unable to accompany her due to COVID-19, the woman was comforted with regular, supportive check-ins from the Social Work intern.

Additionally, the psychosocial team provided ongoing support to Kellogg Cancer Center staff during the COVID-19 crisis. This support was both informal and structured with things like staff meditation sessions and deep breathing exercises at team meetings. Kellogg Cancer Center support groups were switched to virtual meetings this year due to COVID-19 allowing these groups to continue to offer support while maintaining safety.

Integrative Medicine Benefit Success

The third annual benefit concert supporting integrative medicine services for Kellogg Cancer Center patients was the biggest success to date, raising close to \$70,000.

The January 2020 sold-out event at Metro in Chicago featured the acclaimed band, Sons of the Silent Age performing David Bowie's "The Rise and Fall of Ziggy Stardust and the Spiders from Mars" and "Station to Station." The band was once again joined on stage by actor Michael Shannon.

The benefit helps provide scholarships for integrative medicine services including acupuncture, massage therapy, nutrition guidance, talk therapy, and integrative physician consults for pediatric and oncology patients who would not otherwise have access to these important treatments.

continued >



Kellogg Cancer Center patients benefit from a range of integrative medicine services including acupuncture and Traditional Chinese Medicine and bodywork that can help offset side effects, increase energy and relaxation, and add to the healing process. Acupuncturist Rena Zaid (left) is one of the Integrative Medicine team members who works with patients throughout their cancer journey.

During the pandemic, scholarship patients have continued to receive therapies to help manage their symptoms while also optimizing their immune function and the relaxation response.

Oncology Nutrition Services

Kellogg Cancer Center dietitians continued to expand their reach with the “Healthy Eating During Treatment” presentation on NorthShore’s website while also providing additional information through the *Healthy You* blog. Registered dietitian-nutritionists (RDNs) with expertise in oncology support patients and their families as maintaining good nutrition helps improve patient

outcomes, as well as managing symptoms such as unintended weight gain or loss, nausea, taste changes and bowel changes.

Phone consultations were implemented during the pandemic to ensure that patients had continued access to critical information and nutrition counseling during treatment. Kellogg Cancer Center RDNs also work with support groups and patients beyond treatment. This year, our dietitians presented at a survivorship program in March, a SPOHNC (Support for People with Oral and Head and Neck Cancer) support group in June, and the NorthShore Prostate Education and Us TOO Support Group in October.



In partnership with the American Cancer Society's Making Strides Against Breast Cancer fundraiser, food trucks visited NorthShore Glenbrook and Highland Park Hospitals and proceeds from sales supported NorthShore's Kellogg Team fundraising efforts.

Community Partners

Kellogg Cancer Center maintains an important array of partnerships and collaborations with community organizations. The staff assists with virtual programs and support groups and stays connected in the immediate community and beyond to ensure that ongoing education and advocacy efforts have stayed strong even during the pandemic.

Kellogg Cancer Center team members participated in many virtual community outreach events this year with Cancer Wellness Center, Imerman Angels, American Cancer Society, Lungevity Foundation, Respiratory Health Association, Lung Cancer Research Foundation, Us TOO and others as a way to come together safely as a community.

Patients and caregivers were supported throughout COVID-19 with access to cancer-related webinars, support groups, classes and tips on staying connected virtually.

A partnership with Niles Township High School District 219 brought virtual cancer prevention and education classes to students. Carol Rosenberg, MD, Director of Preventive Health Initiatives at NorthShore, taught “Top 10 Real Truths about Cancer Prevention” designed to help participants learn to differentiate science from rumor regarding the role that food, body weight, supplements, alcohol, smoking and other lifestyle strategies play in cancer prevention.

Your Support Makes a Real Difference

At the Kellogg Cancer Center, our dedicated team of outstanding physicians, nurses and other care providers aggressively pursue the latest in novel treatments and highly effective care plans—ones that are equal to or rival nationally recognized cancer centers across the country. Compassion in an environment that promotes best practices through advanced research, clinical trials, personalized medicine and many years of collective experience is paramount and drives the work we do every day.

Kellogg Cancer Center’s patient-centered approach is at the core of everything we do, and philanthropy plays an integral role in its success. Advances in science and technology are moving faster than ever before. Having access to critical resources is key to staying in front and nimble enough to respond to these lifesaving discoveries.

When you donate to Kellogg Cancer Center, you help ensure that everyone receives the best care possible with personalized care plans tailored specifically for the individual using the latest in diagnostics and treatments. As a result, you help save and improve the lives of thousands of patients annually—family, friends and your neighbors. Your impact is enormous.

The good news is more people are beating cancer than ever before thanks to new discoveries, advances in genetics, screening, and targeted therapies like immunotherapy and advanced chemotherapy. Patients have more options now, delivering better outcomes and brighter futures.

We are proud of how far we’ve come and know we still have a ways to go in our pursuit to find a cure. Without question, donors are helping move the needle in the right direction.

To learn more about how you can support Kellogg Cancer Center, please call **(224) 364-7200** or visit foundation.northshore.org.

Brain Tumors

A071101 Phase II randomized trial comparing the efficacy of heat shock protein-peptide complex-96 (HSPPC-96) (NSC #725085, Alliance IND #15380) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma multiforme (GBM)

A221101 Phase III randomized, double-blind, placebo-controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue in patients with glioblastoma multiforme

Tocagen/Tg 511-15-01 A Phase II/III randomized, open-label study of Toca 511, a retroviral replicating vector, combined with Toca FC versus standard of care in subjects undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma

ICT 107 STING (Study of Immunotherapy in Newly Diagnosed Glioblastoma) A Phase III randomized, double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

A071102 A Phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation

AbbVie/M13-813 A randomized, placebo-controlled Phase IIb/III study of ABT-414 with concurrent chemoradiation and adjuvant temozolomide in subjects with newly diagnosed glioblastoma multiforme (GBM) with epidermal growth factor receptor (EGFR) amplification (Intelligence 1)

CDX110-05 Expanded access (compassionate use) treatment protocol, rindopepimut (CDX-110)

AbbVie Preapproval Access Preapproval access of ABT-414 for treatment of glioblastoma multiforme (GBM)

Breast Cancer

A0011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

A0011502 A randomized Phase III double-blind placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2-negative breast cancer: The ABC Trial

S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (pN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Gastrointestinal Cancer

NRG-GI004/SWOG-S1610 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

EA2165 A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High-Risk Anal Cancer

A021502 A Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

UC14-0594 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma

Novocure: Panova-3 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally Advanced Pancreatic Adenocarcinoma

RTOG 1112 Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

A021703 Randomized, Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Genitourinary Cancer

AFT-19 A Phase III Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

PCCTC c16-168 A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

EA8163 Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel; The CHAARTED 2 Trial

Johns Hopkins J1557 Overcoming Drug Resistance in Metastatic Castration-Resistant Prostate Cancer with Novel Combination of TGF- β Receptor Inhibitor LY2157299 and Enzalutamide: A Randomized Multi-Site Phase II Study

EA8143 A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Gynecologic Cancer

NRG-GY005 A randomized Phase II/III study of the combination of cediranib and olaparib compared to cediranib or olaparib alone, or standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube or primary peritoneal cancer

GOG0264 A randomized Phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed advanced-stage and recurrent chemo-naïve stage sex cord-stromal tumors of the ovary

UC13-1235 Randomized, placebo-controlled Phase II trial of metformin in conjunction with chemotherapy followed by metformin maintenance therapy in advanced-stage ovarian, fallopian tube and primary peritoneal cancer adjuvant treatment

Pilot Study Pilot study of the impact of early palliative care on quality of life in recurrent ovarian, fallopian tube and primary peritoneal cancer

AGCT1531 A Phase III Study of Active Surveillance for Low-Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard-Risk Pediatric and Adult Patients with Germ Cell Tumors

NRG-GY009 A Randomized Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND 134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum-Resistant Ovarian Cancer

GOG-3026 A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum NRG-GY020: Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NCT# 04214067)

NRG-GY020 Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NCT# 04214067)

NRG-GY018 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

NRG-GY014 A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

Head and Neck Cancers

HCN Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes

Merck 3475-689 A Phase III Randomized, Open-Label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable, Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Enzychem EC-18-202 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EC-18 in Altering the Severity and Course of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation Therapy for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx

EA3163 Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Postoperative Radiation Versus Surgery and Postoperative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma

NRG HN005 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Hematology

Connect® MDS/AML The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

E1910 Phase III randomized trial of blinatumomab for newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia in adults

CIBMTR Research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries

TG Therapeutics TGR-205 A Phase IIb Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 Alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell ALL

UC16-1138 Open-Label, Single-Arm, Phase 2 Study of Initial Treatment with Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low-Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

EA9161 A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib to Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

AstraZeneca D8220R00004 Treatment Patterns, Outcomes and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents

Lung Cancer

LungMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

S1900A A Phase II Study of Rucaparib in Patients with Genomically LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

S1800A A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients with Previously Treated Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

EA5163/S1709 INSIGNA A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy Induction/Maintenance or Post-Progression in Advanced, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

NRG LU003 A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol

E4512 A Phase III double-blind trial for surgically resected early-stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein

EH15-122 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A081105 Randomized, double-blind, placebo-controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

S1900C A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)

continued >

NRG-LU005 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (MPDL3280A)

Mirati 516-005 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

Sarcoma Skin Cancer

EA6141 Randomized Phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

EA6134 A Randomized Phase III Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression Versus Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

Regeneron Cemiplimab Survivorship Epidemiology (CASE) Study

Castle Biosciences Development and Validation of Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Other

EAY131 Molecular Analysis for Therapy Choice (MATCH)

EAY131-A A Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

EAY131-C2 Crizotinib in patients with tumors with MET exon 14 deletion

EAY131-E AZD9291 in patients with tumors having EGFR T790M mutations (except non-small cell lung cancer) or rare activating mutations of EGFR

EAY131-J Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification

EAY131-K1 Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications

EAY131-K2 Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions

EAY131-L Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

EAY131-M Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

EAY131-T GDC-0449 (vismodegib) in patients with tumors (except basal cell skin carcinoma) with smoothened (SMO) or patched 1 (PTCH1) mutations

EAY131-V Phase II study of sunitinib in patients with tumors with c-kit mutations (excluding GIST, renal cell carcinoma or pancreatic neuroendocrine tumor)

EAY131-Z1C Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification

EAY131-Z1E LOX0-101 in Patients with Tumors with NTRK Fusions

EAY131-Z1F Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

EAY131-Z1G Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result

EAY131-Z1H Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

EAY131-Z1K Ipatasertib in Patients with Tumors with AKT Mutations

EAY131-Z1L Phase 2 Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions or Non-V600E, Non-V600K BRAF Mutations

A221602 Olanzapine with or without fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double-Blind, Placebo-Controlled Trial

ASCO Survey on COVID-19 in Oncology (ASCO) Registry

Breast Surgery

EH15-297 A randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy—Alliance A011202

EH15-308 Using genetic risk scores to assess the efficacy of mammography screening among women diagnosed with breast cancer

EH16-063 Germline genetic profiles associated with contralateral breast cancer patients

EH14-020 Piloting an In-Visit Decision Aid for Surgical Decision-Making in Breast Cancer Patients

EH17-026 A Database of Contralateral Breast Cancer at NorthShore University HealthSystem

EH17-045 Impact of an In-Visit Decision Aid on Uninformed Decision-Making for Contralateral Prophylactic Mastectomy

EH16-343 Retrospective Review of HER2/neu Positive Breast Cancer Patients to Examine Loco-Regional Recurrence Rates

EH18-203 Mindfulness-Enhanced Decision Intervention to Aid Treatment Election—Breast Cancer

EH17-072 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS

EH17-209 Genetic Determinants of Cooperative Interactions on Breast Cancer Intratumor Heterogeneity

EH18-243 Tell Me Where It Hurts: The Ergonomic Effects of Mastectomies on the Operating Surgeon

EH10-081-ACOSOG Z1071 A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis

EH88-077 The Establishment and Maintenance of the NorthShore University HealthSystem Comprehensive Data Registry for Breast Surgeries and Breast Tissue Bank

EH19-218 Development of a Value Preference Scale for Patients Undergoing Breast Cancer Surgery

EH20-301 WhySurg for Men: A Male Breast Cancer Survey for Men with Breast Cancer

EH20-171 CROWN Study: COVID-19-Related Oncologist's Concerns about Treatment Delays and Physician Well-Being

EH18-074 MarginProbe System U.S. Post-Approval Study Protocol CP-07-001

EH19-074 A Prospective, Multicenter Investigation of the da Vinci Xi Surgical System in Nipple-Sparing Mastectomy (NSM) Procedures

EH20-348 Retrospective, Multicenter Study of Open Nipple-Sparing Mastectomy (NSM)

Colorectal Surgery

EH12-468 N1048 A Phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision

Head and Neck Surgery

EH17-116 Lipid Tissue from Head and Neck Cancer

Pancreatic Cancer

EH18-265 A Phase III Multicenter, Open-Label, Randomized, Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy

EH08-197T Clinical pancreatic cancer database

EH13-433 Comprehensive Assessments for Clinical Care and Surgical Management Among Individuals with Pancreatic Pathology

EH02-186 The Pancreatic Sample Repository

EH17-132 Assessment of Tumor and Treatment Factors as Predictors of Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma Undergoing Pancreatoduodenectomy, and Efficacy of Pharmacologic Prophylaxis

Lung and Esophageal Cancer

EH98-136 Establishment and maintenance of a comprehensive thoracic tumor data registry and biorepository

EH15-121 E4512 A Phase III double-blind trial for surgically resected early-stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein

EH15-122 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

EH15-123 A081105 Randomized, double-blind, placebo-controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

EH16-268 EA5142 Adjuvant nivolumab in resected lung cancers (ANVIL): A randomized Phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers

EH18-162 Inherited Cancer Panel Performance in Predicting Outcomes Among Patients Diagnosed with Lung Cancer

EH16-356 Clinical Characteristics of Anti-PD-1/PD-L1 relapses in Non-Small Cell Lung Cancer (NSCLC)

EH16-079 Retrospective chart review study to look at adequacy of lymph node staging in patients undergoing curative anatomic resection for non-small cell lung cancer

EH16-362 Natural History of Indeterminate Lung Nodules

Thyroid Surgery

EH14-058 The establishment of a multidisciplinary comprehensive database of patients for thyroid nodular disease

Genitourinary Cancer

EH09-043 A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

EH10-089 Periprostatic fat as a promoter of prostate cancer progression

EH10-379 Three-dimensional transrectal ultrasound for prostate cancer diagnosis and surveillance

EH13-049 Compliance and outcomes with penile rehabilitation in men after prostate cancer treatment

EH13-088 Mind-body health in uro-oncology

EH13-250 Cancer susceptibility: The ICPCG study (International Consortium for Prostate Cancer Genetics)

EH13-446 A retrospective review of patients who have been removed from study EH09-043: A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

EH14-133 The Lived Experience of Men with Sexual Dysfunction After Prostate Cancer Treatment

EH15-240 Urologic oncology: Costs and complications

EH14-206 Nanocytology to mitigate overdiagnosis of prostate cancer

EH14-361 SPORE Project 1: Impact of Germline Genetic Variants and Failure of Active Surveillance for Prostate Cancer

EH16-009 Clinical validation of a urine-based assay with genomic and epigenomic markers for predicting recurrence during non-muscle-invasive bladder cancer surveillance

EH16-183 Evaluation of the utility of the prostate health index in routine clinical practice

EH16-202 Detecting copy number alterations (CNAs) of MYC and PTEN in biopsy samples to predict clinical outcomes in prostate cancer

EH16-232 Trends in upper tract urothelial treatment

EH16-240 Timing of artificial urinary sphincter placement

EH15-124 Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education (REASSURE ME)

EH15-403 Mindfulness online for symptom alleviation and improvement in cancer of the prostate (MOSAIC-P)

EH16-236 Novel genetic markers for predicting clinical outcomes in patients with high-grade superficial bladder cancer

EH16-239 The impact of using genetic risk scores (GRSs) for inherited risk assessment of prostate cancer

EH16-237 A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance (ENACT)

EH16-387 Risk-Stratification of Prostate Cancers via Field Carcinogenesis Nanocytology

2019-2020 Research Publications

Aaron-Brooks LM, Sasaki T, Vickman RE, Wei L, Franco OE, Ji Y, Crawford SE, Hayward SW. Hyperglycemia and macrophage infiltration are associated with stromal and epithelial prostatic hyperplasia in the non-obese diabetic (NOD) mouse. *Prostate*. 2019 Jun;79(9):980-993. doi: 10.1002/pros.23809. Epub 2019 Apr 18. PMID: 30999385

Al Abbas AI, Borrebach JD, Pitt HA, Bellon J, **Hogg ME**, Zeh HJ 3rd, Zureikat AH. Development of a Novel Pancreatoduodenectomy-Specific Risk Calculator: An Analysis of 10,000 Patients. *J Gastrointest Surg*. 2020 Jul 15. PMID: 32671801

Al Abbas AI, Falvello V, Zenati M, Mani A, **Hogg ME**, Zeh HJ 3rd, Singhi A, Bahary N, Zureikat AH. Impact of adjuvant chemotherapy regimen on survival outcomes in immunohistochemical subtypes of ampullary carcinoma. *J Surg Oncol*. 2019 Dec 15. doi: 10.1002/jso.25808. PMID: 31840257

Al Abbas AI, **Hogg ME**. ASD Author Reflections: Serum CA19-9 Utility in Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy. *Ann Surg Oncol*. 2020 Jun;27(6):2015-2016. doi: 10.1245/s10434-020-08342-8. Epub 2020 Mar 14. PMID: 32172332

Al Abbas AI, Zenati M, Reiser CJ, Hamad A, Jung JP, Zureikat AH, Zeh HJ 3rd, **Hogg ME**. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. *Ann Surg Oncol*. 2020 Jun;27(6):2007-2014. PMID: 31898105

Alikhan MB, Al-Kawaaz M, **Kaul K, Sabatini L**. Practical Concepts, Current Challenges and Technical Advances in Clinical Next-Generation Sequencing Assays for Solid Tumors. In: *Advances in Molecular Pathology*, 2:163-175, Elsevier, 2019.

Antony AK, Poirier J, Madrigano A, **Kopkash K**, Robinson E. Evolution of the Surgical Technique for "Breast in a Day" Direct to Implant Breast Reconstruction: Transitioning from Dual Plane to Pre-Pectoral Implant Placement. *Plast Reconstr Surg*. 2019 Jun;143(6):1547-1556. doi: 10.1097/PRS.0000000000005627. PMID: 31136464

Asbun HJ, Moekotte AL, Vissers FL, Kunzler F, Cipriani F, Alseidi A, ... **Hogg ME**, ... **Talamonti MS**, et al. International Study Group on Minimally Invasive Pancreas Surgery (I-MIPS). The Miami International Evidence-Based Guidelines on Minimally Invasive Pancreas Resection. *Ann Surg*. 2020 Jan;271(1):1-14. doi: 10.1097/SLA.0000000000003590. PMID: 31567509

Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, **Helfand BT, Hutten Selkirk C**, et al. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. *BJU Int*. 2019 Feb;123(2):284-292. doi: 10.1111/bju.14412. Epub 2018 Jun 22. PMID: 29802810

Bartlett DL, Howe JR, Chang G, Crago A, **Hogg M**, Karakousis G, Levine E, Maker A, Mamounas E, McGuire K, Merchant N, Shibata D, Sohn V, Solorzano C, Turaga K, White R, Yang A, Yoon S; Society of Surgical Oncology. Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations. *Ann Surg Oncol*. 2020 Jun;27(6):1717-1720. PMID: 32270420

Beane JD, Zenati M, Hamad A, **Hogg ME**, Zeh HJ 3rd, Zureikat AH. Robotic pancreatoduodenectomy with vascular resection: Outcomes and learning curve. *Surgery*. 2019 Jul;166(1):8-14. doi: 10.1016/j.surg.2019.01.037. Epub 2019 Mar 21. PMID: 30905468.

Behdad A, Boddy CS, Fought AJ, Taxter T, Falkiewicz MK, Ayers E, Chen QC, Chen YH, Karmali R, Pro B, Winter JN, Landsburg DJ, Gordon LI, **Kaplan JB**. Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. *Leuk Lymphoma*. 2019 Dec;60(13):3266-3271. doi: 10.1080/10428194.2019.1622099. Epub 2019 Jun 21. PMID: 31225766

Belopolsky Y, Grinblatt DL, Dunnenberger HM, Sabatini LM, Joseph NE, Fimmel CJ. A Case of Severe, Nilotinib-Induced Liver Injury. *ACG Case Rep J*. 2019 Feb 25;6(2):e00003. doi: 10.14309/crj.0000000000000003. eCollection 2019 Feb. PMID: 31616712

Belopolsky Y, Khan MQ, Sonnenberg A, Davidson DJ, Fimmel CJ. Ketogenic, Hypocaloric Diet Improves Nonalcoholic Steatohepatitis. *J Transl Int Med*. 2020 May 9;8(1):26-31. doi: 10.2478/jtjm-2020-0005. eCollection 2020 Mar. PMID: 32435609

Benirschke RC, McElvania E, Thomson R, **Kaul K**, Das S. Clinical Impact of Rapid Point-of-Care Polymerase Chain Reaction Influenza Testing in the Urgent Care Setting. *J Clin Microbiol*. 2019 Feb 27;57(3):e01281-18. doi: 10.1128/JCM.01281-18. Print 2019 Mar. PMID: 30602445

Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, **Khandekar JD**, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtress BA, Adams GL, Pandya KJ. Double-blind, randomized phase 3 trial of low-dose 13-cis-retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). *Cancer*. 2017 Dec 1;123(23):4653-4662. doi: 10.1002/cncr.30920. Epub 2017 Aug 7. PMID: 28786105

Bleicher R, **Chang C, Wang C**, Goldstein L, Kaufman C, Moran M, Pollitt K, Suss N, **Winchester DP**, Tafra L, **Yao K**. Treatment Delays from Transfers of Care and Their Impact on Breast Cancer Quality Measures. *Breast Cancer Res Treat*. 2019 Feb;173(3):603-617. doi: 10.1007/s10549-018-5046-x. Epub 2018 Nov 15. PMID: 30443881

Boisen ML, McQuaid AJ, Esper SA, Holder-Murray J, Zureikat AH, **Hogg ME**, Paronish J, Subramaniam K. Intrathecal Morphine Versus Nerve Blocks in an Enhanced Recovery Pathway for Pancreatic Surgery. *J Surg Res*. 2019 Jul 3;244:15-22. doi: 10.1016/j.jss.2019.05.049. [Epub ahead of print] PubMed PMID: 31279259.

Boone BA, Zenati MS, Rieser C, Hamad A, Al Abbas A, Zureikat AH, **Hogg ME**, Neal MD, Zeh HJ 3rd. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. *Ann Surg Oncol*. 2019 May;26(5):1503-1511. doi: 10.1245/s10434-018-07148-z. Epub 2019 Jan 16. PMID: 30652227

Borahay MA, Wethington SL, Wang KC, Christianson MS, Martin S, Lawson SM, ... **Lippitt MH**, et al. Patient-Centered, Gynecology-Specific Prioritization of Nonurgent Surgeries During the COVID-19 Pandemic: Proposal of a Novel Scoring System. *J Minim Invasive Gynecol*. Sep-Oct 2020;27(6):1429-1433. doi: 10.1016/j.jmig.2020.05.026. Epub 2020 Jun 3. PMID: 32504823

Borhani AA, Dewan R, Furlan A, Seiser N, Zureikat AH, Singhi AD, Boone B, Bahary N, **Hogg ME**, Lotze M, Ili HJZ, Tublin ME. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. *AJR Am J Roentgenol*. 2019 Dec 4;1-8. doi: 10.2214/AJR.19.21152. [Epub ahead of print] PMID: 31799875

Bortz MD, Kuchta K, Winchester DJ, Prinz RA, Moo-Young TA. Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. *Surgery*. 2020 Jul 15:S0039-6060(20)30183-5. doi: 10.1016/j.surg.2020.04.003. Online ahead of print. PMID: 32682508

Boysen WR, Cohen AJ, Kuchta K, **Park S**, Milose J. Combined Placement of Artificial Urinary Sphincter and Inflatable Penile Prosthesis Does Not Increase Risk of Perioperative Complications or Impact Long-Term Device Survival. *Urology*. 2019 Feb; 124:264-270. doi: 10.1016/j.urolgy.2018.10.033. Epub 2018 Oct 26. PMID: 30786981

Brown JA, Jung JP, Zenati MS, Simmons RL, Al Abbas AI, **Hogg ME**, Zeh HJ, Zureikat AH. Video review reveals technical factors predictive of biliary stricture and cholangitis after robotic pancreaticoduodenectomy. *HPB (Oxford)*. 2020 Jul 6:S1365-182X(20)31041-8. PMID: 32646806

Brown JA, Zenati MS, Simmons RL, Al Abbas AI, Chopra A, Smith K, Lee KKW, **Hogg ME**, Zeh HJ, Panicia A, Zureikat AH. Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes and Risk Factors. *J Gastrointest Surg*. 2020 Jul;24(7):1581-1589. PMID: 32410174

Brownlee A, **Krantz SB**. Increasing T stage is associated with the need for more extensive lymph node assessment in clinical stage I non-small cell lung cancer. *J Thorac Dis*. 2019 Sep;11(Suppl 15):S1927-S1929. doi: 10.21037/jtd.2019.08.119. PMID: 31632789

Cai J, Ramanathan R, Zenati MS, Al Abbas AI, **Hogg ME**, Zeh HJ, Zureikat AH. Robotic Pancreatoduodenectomy Is Associated with Decreased Clinically Relevant Pancreatic Fistulas: A Propensity-Matched Analysis. *J Gastrointest Surg*. 2020 May;24(5):1111-1118. doi: 10.1007/s11605-019-04274-1. Epub 2019 Jul 2. PMID: 31267434

Carter HB, **Helfand B**, Mamawala M, **Wu Y**, Landis P, Yu H, Wiley K, **Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB**, Zheng SL, Isaacs WB, **Xu J**. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. *Eur Urol*. 2019 May;75(5):743-749. doi: 10.1016/j.euro.2018.09.021. Epub 2018 Oct 8. PMID: 30309687

Catenacci DVT, Chase L, Lomnicki S, Karrison T, **de Witton Marsh R**, Rampurwala MM, et al. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX with Margin-Negative Resection Rates and Pathologic Response Grades Among Patients with Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. *JAMA Netw Open*. 2020 Feb 5;3(2):e1921290. doi: 10.1001/jamanetworkopen.2019.21290. PMID: 32058557

Cella D, Smith AR, Griffith JW, Flynn KE, Bradley CS, Gillespie BW, Kirkali Z, **Talaty P**, Jelovsek JE, **Helfand BT, Talaty P**, Weinfurt KP; LURN Study Group. A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire. *Neurourol Urodyn*. 2019 Aug;38(6):1751-1759. doi: 10.1002/nau.24067. Epub 2019 Jun 21. PMID: 31225927

Cella D, Smith AR, Griffith JW, Kirkali Z, Flynn KE, Bradley CS, Jelovsek JE, Gillespie BW, **Helfand BT, Talaty P**, Weinfurt KP; LURN Study Group. A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10. *J Urol*. 2020 Jan;203(1):164-170. doi: 10.1097/JU.0000000000000465. Epub 2019 Jul 31. PMID: 31364922

Chatterjee A, Gass J, Krishnabhai PK, Holmes D, **Kopkash K**, Peiris L, Peled A, Ryan J, El-Tamern M, Reiland J. A Consensus Definition and Classification System of Oncoplastic Surgery Developed by the American Society of Breast Surgeons. *Ann Surg Oncol*. 2019 Oct;26(11):3436-3444. doi: 10.1245/s10434-019-07345-4. Epub 2019 Apr 11. PMID: 30977016

Chugh R, Griffin KA, Davis EJ, Thomas DG, Zavala JD, Metko G, **Brockstein B**, Undevia SD, Stadler WM, Schutze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: A phase 1 study using the TITE-CRM model. *Ann Oncol* 2019 Aug 1;30(8) 1405. doi: 10.1093/annonc/mdy557

Cohen AJ, Adamsky MA, Nottingham OC, Pruitt J, Lapin B, Wang CH, **Park S**. Impact of Statin Intake on Kidney Stone Formation. *Urology*. 2019 Feb; 124:57-61. doi: 10.1016/j.urolgy.2018.01.029. Epub 2018 Feb 5. PMID: 29421299

Dai S, Lv Y, **Xu W, Yang Y**, Liu C, Dong X, Zhang H, Prabhakar BS, Maker AV, **Seth P**, Wang H. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice. *Cancer Gene Ther*. 2020 Apr 20. doi: 10.1038/s41417-020-0173-z. Online ahead of print. PMID: 32307442

Das S, Mangold KA, Shah NS, Peterson LR, Thomson RB, **Kaul KL**. Performance and Utilization of a Laboratory-Developed Nucleic Acid Amplification Test (NAAT) for the Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in a Low-Prevalence Area. *Am J Clin Pathol*. 2020 Jun 8;154(1):115-123. doi: 10.1093/ajcp/aqaa031. PMID: 32249294

Diaz Quintero LA, Fuentes HE, **Tafur AJ, Majmudar K, Salazar Adum JP, Golemi I, Pas LH, Stocker S, Talamonti MS**. Pancreatic cancer thromboembolic outcomes: Rate of thrombosis after adenocarcinoma and non-adenocarcinoma pancreatic cancer surgery. *Int Angiol*. 2019 Jun;38(3): 194-200. doi: 10.23736/S0392-9590.19.04127-0. PMID: 31112026

Dietz JR, Moran MS, ...Nelson H, **Yao KA**. Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 Pandemic Breast Cancer Consortium. *Breast Cancer Res Treat*. 2020 Jun;181(3):487-497. doi: 10.1007/s10549-020-05644-z. Epub 2020 Apr 24. PMID: 2333293

Ellis RJ, Zhang LM, Ko CY, Cohen ME, Bentröm DJ, Bilimoria KY, Yang AD, **Talamonti MS**, Merkow RP. Variation in Hospital Utilization of Minimally Invasive Distal Pancreatectomy for Localized Pancreatic Neoplasms. *J Gastrointest Surg*. 2019 Nov 25. doi: 10.1007/s11605-019-04414-7. Online ahead of print. PMID: 31768832

Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, ... **Hulick PJ**, et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet*. 2020 Jan;52(1):56-73. doi: 10.1038/s41588-019-0537-1. Epub 2020 Jan 7. PMID: 31911677

Fantus RJ, Cohen A, Riedinger CB, **Kuchta K, Wang CH, Yao K, Park S**. Facility-level analysis of robot utilization across disciplines in the National Cancer Database. *J Robot Surg*. 2019 Apr;13(2):293-299. doi: 10.1007/s11701-018-0855-9. Epub 2018 Jul 30. PMID: 30062641

continued >

Fantus RJ, Chang C, Hehemann MC, Bennett NE, Brannigan RE, **Helfand BT**, Halpern JA. The association between guideline-based exercise thresholds and low testosterone among men in the United States. *Andrology*. 2020 Jul 1. doi: 10.1111/andr.12849. Online ahead of print. PMID: 32609423

Fantus RJ, Halpern JA, **Chang C**, Keeter MK, Bennett NE, **Helfand B**, Brannigan RE. The Association Between Popular Diets and Serum Testosterone Among Men in the United States. *J Urol*. 2020 Feb;203(2):398-404. doi: 10.1097/JU.0000000000000482. Epub 2019 Aug 8. PMID: 31393814

Fantus RJ, Halpern JA, **Chang C**, Keeter MK, Brannigan RE, **Helfand BT**, Bennett NE. The association of popular diets and erectile function among men in the United States. *Int J Impot Res*. 2020 Jun 2. doi: 10.1038/s41443-020-0313-x. Online ahead of print. PMID: 32488209

Fantus RJ, Helfand BT. Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools. *Clin Chem*. 2019 Jan;65(1):74-79. doi: 10.1373/clinchem.2018.286658. Epub 2018 Nov 20. PMID: 30459162

Fantus RJ, Riedinger CB, **Chang C**, **Helfand BT**. The Association Between Tetrahydrocannabinol and Lower Urinary Tract Symptoms Utilizing the National Health and Nutrition Examination Survey. *Urology*. 2019 Jan;123:120-125. doi: 10.1016/j.urol.2018.06.054. Epub 2018 Aug 21. PMID: 30142408

Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, ... **Hulick PJ**, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genet Epidemiol*. 2020 Jul;44(5):442-468. doi: 10.1002/gepi.12288. Epub 2020 Mar 1. PMID: 32115800

Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, ... **Hulick PJ**, et al. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nat Commun*. 2019 Apr 15;10(1):1741. doi: 10.1038/s41467-018-08053-5. PMID: 30988301

Frankenstein Z, Basanta D, **Franco OE**, Gao Y, **Javier RA**, Strand DW, Lee M-J, **Hayward SW**, Ayala G, Anderson ARA. Stromal Reactivity Differentially Drives Tumor Cell Evolution and Prostate Cancer Progression. *Nat Ecol Evol*. 2020 Jun;4(6):870-884. doi: 10.1038/s41559-020-1157-y. Epub 2020 May 11. PMID: 32393869

Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, ... **Hulick PJ**, et al. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Hum Mutat*. 2019 Oct;40(10):1781-1796. doi: 10.1002/humu.23804. Epub 2019 Jul 3. PMID: 31112363

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, ... **Kaplan JB**, et al. Survival Outcomes of Younger Patients with Mantle Cell Lymphoma Treated in the Rituximab Era. *J Clin Oncol*. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7. PMID: 30615550

Girgis MD, Zenati MS, King JC, Hamad A, Zureikat AH, Zeh HJ, **Hogg ME**. Oncologic Outcomes After Robotic Pancreatic Resections Are Not Inferior to Open Surgery. *Ann Surg*. 2019 Oct 28. doi: 10.1097/SLA.0000000000003615. [Epub ahead of print] PMID: 31663967

Giri VN, Knudsen KE, ... **Polascik TJ**, **Helfand BT**, ... **Sartor O**, Isaacs WB, **Xu J**, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *J Clin Oncol*. 2020 Jun 9;JCO2000046. doi: 10.1200/JCO.20.00046. Online ahead of print. PMID: 32516092

Gniadek TJ, Mallek J, Wright G, Saporito C, AbiMansour N, Tangazi W, Rogers G, Zahara Z, Cummings G, **Kaul K**, Kang J. Expansion of hospital-based blood collections in the face of COVID-19-associated national blood shortage. *Transfusion*. 2020 Jul;60(7):1470-1475. doi: 10.1111/btf.15869. Epub 2020 Jun 24. PMID: 32445417

Gordon LI, **Kaplan JB**, ... **Stumpo K**, Shou Y, Carpio C, Bosch F. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. *Clin Cancer Res*. 2020 Apr 23. doi: 10.1158/1078-0432.CCR-19-3239. Online ahead of print. PMID: 32327472

Gremore TM, **Brockstein B**, Porter LS, Brenner S, Benfield T, Baucom DH, Sher TG, Atkins D. Couple-based communication intervention for head and neck cancer: A randomized pilot trial. *Support Care Cancer*. 2020 Oct 26. DOI: 10.1007/s00520-020-05848-5. Online ahead of print PMID 33106976

Halpern JA, **Fantus RJ**, Chang C, Keeter MK, **Helfand B**, Bennett NE, Brannigan RE. Effects of nonsteroidal anti-inflammatory drug (NSAID) use upon male gonadal function: A national, population-based study. *Andrologia*. 2020 May;52(4):e13542. doi: 10.1111/and.13542. Epub 2020 Feb 18. PMID: 32072663

Haspel RL, Ali AM, Huang GC, Smith MH, Atkinson JB, Chabot-Richards DS, Elliott RM, **Kaul KL**, Powell SZ, Rao A, Rinder HM, Vanderbilt CM, Wilcox R. Teaching Genomic Pathology: Translating Team-Based Learning to a Virtual Environment Using Computer-Based Simulation. *Arch Pathol Lab Med*. 2019 Apr;143(4):513-517. doi: 10.5858/arpa.2018-0153-OA. Epub 2018 Nov 30. PMID: 30500295

Hayward SW. [2020] Immunotherapeutic response in tumors is affected by microenvironmental ROS. *Cancer Res*. 2020 May 1;80(9):1799-1800. doi: 10.1158/0008-5472.CAN-20-0590. PMID: 32366527

Helfand BT, Andrew VP, Siddiqui NY, Liu G, Erickson BA, Helmut ME, Lutgendorf SK, Lai HH, Kirkali Z, LURN Study Group. A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study. *Urology*. 2019 Jul;129:35-42. doi: 10.1016/j.urol.2019.03.014. Epub 2019 Mar 25. PMID: 30922973

Helfand BT, Xu J. Germline testing for prostate cancer prognosis: Implications for active surveillance. *Can J Urol*. 2019 Oct;26(5 Suppl 2):48-49. PMID: 31629432

Hepburn A, Curry E, Moad M, Steele R, Franco OE, Wilson L, Singh P, Buskin A, **Crawford S**, Gaughan L, Mills I, **Hayward SW**, Robson CN, Heer R. Propagation of human prostate tissue from induced pluripotent stem cells. *Stem Cells Transl Med*. 2020 Jul;9(7):734-745. doi: 10.1002/sctm.19-0286. Epub 2020 Mar 14. PMID: 32170918

Hoffman RD, Kragel PJ, **Kaul KL**. Position Paper from the Association of Pathology Chairs: Assessing Autopsy Competency in Pathology Residency Training. *Acad Pathol*. 2019 Feb 5;6:2374289518824057. doi: 10.1177/2374289518824057. eCollection 2019 Jan-Dec. PMID: 30783620

Holoubek SA, Yan H, Khokar AH, Kuchta KM, Winchester DJ, Prinz RA, Moo-Young TA. Aggressive variants of papillary thyroid microcarcinoma are associated with high-risk features, but not decreased survival. *Surgery*. 2020 Jan;167(1):19-27. doi: 10.1016/j.surg.2019.03.030. Epub 2019 Oct 16. PMID: 31627846

Holoubek SA, Yan H, Kuchta KM, Winchester DJ, Moo-Young TA, Prinz RA. Trends in nonoperative management of papillary thyroid microcarcinoma. *J Surg Oncol*. 2020 May;121(6):952-957. doi: 10.1002/jso.25845. Epub 2020 Mar 18. PMID: 32189361

Hoppenot C, Peters P, Cowan M, **Moore ED**, Hurteau J, Lee NK, Yamada SD. Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? *Gynecol Oncol*. 2019 Jul;154(1):177-182. doi: 10.1016/j.ygyno.2019.04.681. Epub 2019 May 2. PMID: 31056111

Huang D, Wu YS, Ye DW, Qi J, Liu F, **Helfand BT, Zheng SL**, Ding Q, Xu DF, **Na R, Xu JF**, Sun YH. Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: Results from a multicenter study in China. *Asian J Androl*. 2020 Jan 10. doi: 10.4103/aj.aja.136_19. Online ahead of print. PMID: 31929198

Jones LR, Zwart MJW, Molenaar IQ, Koerkamp BG, **Hogg ME**, Hlail MA, Besselink MG. Robotic Pancreatoduodenectomy: Patient Selection, Volume Criteria and Training Programs. *Scand J Surg*. 2020 Mar;109(1):29-33. doi: 10.1177/1457496920911815. PMID: 32192422

Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Kharat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, **Brockstein B**, et al. Phase II randomized discontinuation trial of bivanib in patients with advanced solid tumors. *Eur J Cancer*. 2019 Oct; 120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12. PMID: 31522033

Joshi SS, Catenacci DVT, ... **Marsh R**, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. *Clin Cancer Res*. 2020 Jan 1;26(1):18-24. doi: 10.1158/1078-0432.CCR-19-1483. Epub 2019 Sep 26. PMID: 31558477

Kantor O, Bao J, Jaskowiak N, **Yao K**, Tseng J. The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer. *Ann Surg Oncol*. 2020; 27 (2): 352-358. doi: 10.1245/s10434-019-07636-w. Epub 2019 Aug 2. PMID: 31376037

Kantor O, **Barrera E, Kopkash K, Pesce C, Barrera E, Winchester DJ, Yao K**. Are We Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of Oncotype DX® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. *Ann Surg Oncol*. 2019 Oct;26(10):3232-3239. doi: 10.1245/s10434-019-07555-w. Epub 2019 Jul 24. PMID: 31342379

Kantor O, **Chang C**, Bleicher R, Moran M, Connolly JL, Kurtzman SH, **Yao K**. Physician Knowledge of Breast Cancer Recurrence and Contralateral Breast Cancer Risk Is Associated with Increased Recommendations for Contralateral Prophylactic Mastectomy: A Survey of Physicians at NAPBC-Accredited Centers. *Ann Surg Oncol*. 2019; 26(10): 3080-3088. doi: 10.1245/s10434-019-07559-6. Epub 2019 Jul 24. PMID: 31342369

Kantor O, **Pesce C, Kopkash K, Barrera E, Winchester DJ, Kuchta K, Yao K**. Impact of the Society of Surgical Oncology-American Society for Radiation Oncology Margin Guidelines on Breast-Conserving Surgery and Mastectomy Trends. *J Am Coll Surg*. 2019 Jul;229(1):104-114. doi: 10.1016/j.jamcollsurg.2019.02.051. Epub 2019 Mar 20. PMID: 30902638

Kaul KL. The Journal of Molecular Diagnostics: 20 Years of Education and Training. *J Mol Diagn*. 2019 Nov;21(6):933-934. doi: 10.1016/j.jmoldx.2019.09.003. PMID: 31635795

Kaul KL. Precision Pathology. In: *Genomics and Pathology*, Kaul and Netto, eds, Springer, 2019.

Kaul KL. Laboratories and Pandemic Preparedness: A Framework for Collaboration and Oversight. *J Mol Diagn*. 2020 Jul;22(7):841-843. doi: 10.1016/j.jmoldx.2020.05.002. Epub 2020 May 16. PMID: 32425699

Khokar AM, Holoubek SA, Kuchta KM, Winchester DJ, Prinz RA, Moo-Young TA. Survival with Follicular and Hurthle Cell Microcarcinoma Compared to Papillary Thyroid Microcarcinoma: A Population Study of 84,532 Patients. *World J Surg*. 2020 Feb;44(2):469-478. doi: 10.1007/s00268-019-05264-9. PMID: 31863140

Khokar AM, Kuchta KM, Moo-Young TA, Winchester DJ, Prinz RA. Increasing trend of bilateral neck exploration in primary hyperparathyroidism. *Am J Surg*. 2020 Mar;219(3):466-470. doi: 10.1016/j.amjsurg.2019.09.039. Epub 2019 Oct 3. PMID: 31630823

Khokar AM, Kuchta KM, Moo-Young TA, Winchester DJ, Prinz RA. Parathyroidectomy Is Safe in Elderly Patients: A National Surgical Quality Improvement Program Study. *World J Surg*. 2020 Feb;44(2):526-536. doi: 10.1007/s00268-019-05280-9. PMID: 31722077

Kim JS, Liang MI, Prendergast EN, Alldredge J, Datta A, **Hurteau JA, Kirschner CV, Rodriguez G, Vogel TJ**, Brooks RA, Cass I, Cohen JG, Penner KR, **Wang CE, Diaz Moore ES**. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery. *Int J Gynecol Cancer*. 2019 Sep;29(7):1156-1163. doi: 10.1136/igcc-2019-000374. Epub 2019 Jul 27. PMID: 31352365

Kim JS, Turbow J, Rosales R, Thaete LG, Rodriguez GC. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. *Gynecol Oncol*. 2019 Aug;154(2):432-440. doi: 10.1016/j.ygyno.2019.05.022. Epub 2019 Jun 6. PMID: 31178149

Kopkash K, Novak K, Kuchta K, Yashina I, Poli E, **Rabibitt S, Pesce C, Winchester D, Yao K**. The "Nipple Whipple"? A Pilot Study to Assess the Ergonomic Effects of Nipple-Sparing Mastectomy. *Ann Surg Oncol*. 2019 Oct;26(10):3216-3223. doi: 10.1245/s10434-019-07550-1. Epub 2019 Jul 24. PMID: 31342398

Kopkash K, Sisco M, Poli E, Seth A, Pesce C. The modern approach to the nipple-sparing mastectomy. *J Surg Oncol*. 2020 Jul;122(1):29-35. doi: 10.1002/jso.25909. Epub 2020 Mar 26. PMID: 32219847

Kornfeld HW, Mulder LL, Spivey TL, Cortina CS, Madrigano A, **Kopkash KA**. The temporal and financial benefit of intraoperative breast specimen imaging: A pilot study of the Kubtec MOZART. *Breast J*. 2019 Jul;25(4):766-768. doi: 10.1111/bj.13337. Epub 2019 May 13. PMID: 31087462

Kragel PJ, Hoffman RD, **Kaul KL**. Position Paper from the Association of Pathology Chairs: Surgical Pathology Residency Training. *Acad Pathol*. 2019 Feb 5;6:2374289518824054. doi: 10.1177/2374289518824054. eCollection 2019 Jan-Dec. PMID: 30783619

Krantz SB. Robotic Versus VATS Thymectomy for Thymoma. In: *Difficult Decisions in Thoracic Surgery*. 4th Edition. Ferguson, M, ed. Springer. 2020 (in press).

Lemke AA, Thompson J, Hulick PJ, Sereika AW, Johnson C, Oshman L, Dumenberger HM. Primary care physician experiences utilizing a family health history tool with electronic health record-inte-

grated clinical decision support: An implementation process assessment. *J Community Genet.* 2020 Jul;11(3):339-350. doi: 10.1007/s12687-020-00454-8. Epub 2020 Feb 4. PMID: 32020508

Li Y, Xiao F, Zhang A, Zhang D, Nie W, Xu T, Han B, **Seth P**, Wang H, Yang Y, Wang L. Oncolytic adenovirus targeting TGF- β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. *Cell Immunol.* 2020 Feb; 348:104041. doi: 10.1016/j.cellimm.2020.104041. Epub 2020 Jan 11. PMID: 31983398

Liu W, Ruan T, Ji X, Raan D, Sun J, Shi H, **Prinz RA**, Sun J, Pan Z, Jian X, Xu X. The Gli1-Snail axis contributes to Salmonella Typhimurium-induced disruption of intercellular junctions of intestinal epithelial cells. *Cell Microbiol.* 2020 Aug;22(8):e13211. doi: 10.1111/cmi.13211. Epub 2020 Jun 15. PMID: 32329192

Liu H, Zenati MS, Rieser CJ, Al Abbas AI, Lee KK, Singhi AD, Bahary N, **Hogg ME**, Zeh HJ 3rd, Zureikat AH. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. *Surg Oncol.* 2020 Apr 22. PMID: 32318949

Liu W, Zhuang J, Jiang Y, Sun J, **Prinz RA**, Sun J, Jiao X, Xu X. Toll-like receptor signalling cross-activates the autophagic pathway to restrict Salmonella Typhimurium growth in macrophages. *Cell Microbiol.* 2019 Dec;21(12):e13095. doi: 10.1111/cmi.13095. Epub 2019 Aug 26. PMID: 31392811

Mai PL, Huang HQ, Moser RP, **Rodriguez GC**, Greene MH, Hensley ML. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. *Gynecol Oncol.* 2020 Jan;156(1):131-139. doi: 10.1016/j.ygyno.2019.10.026. Epub 2019 Nov 21. *Gynecol Oncol.* 2020. PMID: 31759774

Majmudar K, Northcutt M, Gordon R, Fimmel CJ. Rapid Development of Bleeding Esophageal Varices after Placement of Continuous Flow Left Ventricular Assist Device. *Case Reports Hepatol.* 2019 Nov 6;2019:8410420. doi: 10.1155/2019/8410420. eCollection 2019. Free PMC article. PMID: 31781429

Majmudar K, Quintero LD, Fuentes HE, Stocker S, Tafur AJ, Lee CJ, Talamonti M. Postoperative venous thromboembolism and mortality in patients with pancreatic surgery. *J Surg Oncol.* 2019 Sep;123(3):494-500. doi: 10.1002/jso.25589. PMID: 31222842

Mato A, Nabhan C, Lamanna N, Kay NE, **Grinblatt DL**, Flowers CR, et al. The Connect CLL Registry: Final analysis of 1494 patients with chronic lymphocytic leukemia across 199 U.S. sites. *Blood Adv.* 2020 Apr 14;4(7):1407-1418. doi: 10.1182/bloodadvances.2019001145. PMID: 32271900

Miller M, Bleicher R, Kaufman C, Kurtzman S, **Chang C**, Wang CH, Pollitt KA, Connolly J, **Winchester DP**, Yao K. Impact of Breast Center Accreditation on Compliance with Breast Quality Performance Measures at Commission on Cancer Accredited Centers. *Ann Surg Oncol.* 2019 May;26(5):1202-1211. doi: 10.1245/s10434-018-07108-7. Epub 2019 Jan 25. PMID: 30684159

Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, **Rodriguez GC**, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. *Ann Oncol.* 2020 Sep;31(9):1240-1250. doi: 10.1016/j.annonc.2020.05.019. Epub 2020 May 28. PMID: 32473302

Moekotte AL, Rawashdeh A, Asbun HJ, Coimbra FJ, Edil BH, Jarufe N, Jeyarajah DR, Kendrick ML, Pessaux P, Zeh HJ, Besselink MG, Abu Hilal M, **Hogg ME**; International Evidence-Based Guidelines on Minimally Invasive Pancreas Resection (IG-MIPR). Safe implementation of minimally invasive pancreas resection: A systematic review. *HPB (Oxford).* 2019 Dec 10. pii: S1365-182X(19)33198-3. doi: 10.1016/j.hpb.2019.11.005. [Epub ahead of print] Review. PMID: 31836284

Molins L, Lanuti M, Force S, Woolley S, **Krantz S**, Creedon EE, Schwiens ML, Singleton DW, Waggoner JR, Fryrear R 2nd, Licht P. Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracic Surgery Lobectomy. *J Surg Res.* 2020 Sep; 253:26-33. doi: 10.1016/j.jss.2020.03.023. Epub 2020 Apr 19. PMID: 32320894

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, **Shevrin DH**, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrencic O, Lu C, Carrasquillo JA, Higano CS. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: A phase 1 dose escalation/ randomised phase 2a trial. *Eur J Cancer.* 2019 Jun; 114:107-116. doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11. PMID: 31082669

Na R, Labbate C, Yu H, Shi Z, Fantus RJ, Wang CH, Andriole GL, Isaacs WB, **Zheng SL**, Helfand BT, Xu J. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis. *JAMA Netw Open.* 2019 Dec 2;2(12):e1918145. doi: 10.1001/jamanetworkopen.2019.18145. PMID: 31880795

Nardi F, Fitchew P, Brooks K, **Franco OE**, Cheng K, **Hayward SW**, Welte M, **Crawford SE**. Lipid droplet velocity is a microenvironmental sensor of aggressive tumors regulated by V-ATPase and PEDF. *Lab Invest.* 2019 Dec;99(12):1822-1834. doi: 10.1038/s41374-019-0296-8. Epub 2019 Aug 13. PMID: 31409893

Nardi F, **Franco OE**, Fitchew P, Morales A, **Vickman R**, **Hayward SW**, **Crawford SE**. DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Proteins GM130. *Sci Rep.* 2019 Feb 28;9(1):3035. doi: 10.1038/s41598-019-39537-z. PMID: 30816200

O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, **Merkel DE**, ...Nanda R; Translational Breast Cancer Research Consortium (TBCRC). Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. *Breast Cancer Res Treat.* 2020 Jun;181(3):623-633. doi: 10.1007/s10549-020-05603-8. Epub 2020 May 6. PMID: 32378051

Ogasawara N, Poposki JA, Klingler AI, **Raviv JR**, ...Himi T, Kern RC, Schleimer RP, Kato A. "Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps (MI-19-059). *Mucosal Immunol.* 2020 Jan;13(1):86-95. doi: 10.1038/s41385-019-0215-8. Epub 2019 Oct 22. PMID: 31641233

Okur V, Cho MT, ...Clark Muraresku C, **Hulick PJ**, ...Anyone-Yebo K, Chung WK. De novo variants in HK1 associated with neurodevelopmental abnormalities and visual impairment. *Eur J Hum Genet.* 2019 Jul;27(7):1081-1089. doi: 10.1038/s41431-019-0366-9. Epub 2019 Feb 18. PMID: 30778173

Page EC, Bancroft EK, ...Jia H, **Perschon C**, Duggan D, **Helfand BT**, **Zheng SL**, Xu J. Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts. *Cancer Med.* 2019 Jun;8(6):3196-3205. doi: 10.1002/cam4.2143. Epub 2019 Apr 9. PMID: 30968590

Paintal AS, Brockstein BE. PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma. *Head Neck Pathol.* 2019 Nov 13. doi: 10.1007/s12105-019-01097-z. Online ahead of print. PMID: 31721075

Paniccia A, Gleisner AL, Zenati MS, Al Abbas AI, Jung JP, Bahary N, Lee KKW, Bartlett D, **Hogg ME**, Zeh HJ, Zureikat AH. Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. *Ann Surg Oncol.* 2020 Aug;27(8):2961-2971. doi: 10.1245/s10434-020-08257-4. Epub 2020 Mar 28. PMID: 32222859

Patel VL, Busch EL, Friebe TM, Cronin A, Leslie G, McGuffog L, ...**Hulick PJ**, et al. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. *Cancer Res.* 2020 Feb 1;80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840. Epub 2019 Nov 13. PMID: 31723001

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, **Joseph N**, Pitt J, Brown M, Forde M, **Mangold K**, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, **Kaul K**, Andrade J, White KP, **Talamonti M**, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. *Nat Commun.* 2018 May 4;9(1):1793. doi: 10.1038/s41467-018-04278-6. PMID: 29728604

Polish A, Joseph NE, **Marsh RW**. Pathologic Response to Primary Systemic Therapy with FOLFIRINOX in Patients with Resectable Pancreatic Cancer. *Am J Clin Oncol.* 2019 Oct;42(10):761-766. doi: 10.1097/JCO.000000000000601. PMID: 31569128

Pollyea D, George T, Abedi M, Bejar R, Cogle C, Foucar K, Garcia-Manero G, **Grinblatt D**, et al. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukaemia in the Connect[®] MDS/AML Disease Registry. *eHaem.* May 2020

Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, Jackson M, Dolinsky JS, LaDuca H, **Xu J**, Black MH, **Helfand BT**. Diagnosing hereditary cancer predisposition in men with prostate cancer. *Genet Med.* 2020 May 22. doi: 10.1038/s41436-020-0830-5. Online ahead of print. PMID: 32439974

Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, **Hulick PJ**, **Rodriguez GC**, et al. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *Br J Cancer.* 2019 Jul;121(2):180-192. doi: 10.1038/s41416-019-0492-8. Epub 2019 Jun 19. PMID: 31213659

Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, ...**Rodriguez GC**, et al. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *J Natl Cancer Inst.* 2019 Apr 1;111(4):350-364. doi: 10.1093/jnci/djy132. *J Natl Cancer Inst.* 2019. PMID: 30312457

Rice MK, Hodges JC, Bellon J, Borrebach J, Al Abbas AI, Hamad A, Knab LM, Moser AJ, Zureikat AH, Zeh HJ, **Hogg ME**. Association of Mentorship and a Formal Robotic Proficiency Skills Curriculum with Subsequent Generations' Learning Curve and Safety for Robotic Pancreatoduodenectomy. *JAMA Surg.* 2020 May 20;155(7):607-15. PMID: 32432666

Rodriguez GC, Kauderer J, **Hunn J**, **Thaete LG**, **Watkin WG**, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS. Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/ GOG Study. *Cancer Prev Res (Phila).* 2019 Jun;12(6):401-412. doi: 10.1158/1940-6207.CAPR-18-0383. Epub 2019 Apr 23. PMID: 31015198

Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, **Hensing T**, Shan-karan V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB III. Docetaxel, Oxaliplatin and 5-Fluorouracil (DOF) in metastatic and unresectable gastric/gastroesophageal junction adenocarcinoma: A Phase II study with long-term follow-up. *The Oncologist* 2019; 24:1039-e642; first published on May 28, 2019; doi:10.1634/the-oncologist.2019-0330. PMID: 31138725

Sasaki T, **Franco OE**, Ohishi K, **Filipovich Y**, Ishii K, **Crawford SE**, Takahashi N, Katayama N, **Sugimura Y**, **Hayward SW**. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients. *Prostate.* 2019 Feb;79(3):259-264. doi: 10.1002/pros.23730. Epub 2018 Oct 28. PMID: 30370673

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators* (**Saha P**). Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med.* 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. PMID: 32101663

Sener SF, **Khandekar J**. In Memoriam, Henry T. Lynch, MD. *J Surg Oncol.* 2019 Oct;120(5):817-818. doi: 10.1002/jso.25627. Epub 2019 Jul 8 (editorial).

Seth P. Call for Special Issue Papers: Oncolytic Viruses and Cancer Immunotherapy. *Hum Gene Ther.* 2020 Jun 19. doi: 10.1089/hum.2020.29127.cfp. Online ahead of print. PMID: 32559407

Shah N, Konchak C, Chertok D, Au L, Kozlov A, Ravichandran U, McNulty P, Liao L, Steele K, Kharasch M, Boyle C, Hensing T, **Lovinger D**, **Birnberg J**, **Solomonides A**, **Halasyamani L**. Clinical Analytics Prediction Engine (CAPE): Development, electronic health record integration and prospective validation of hospital mortality, 180-day mortality and 30-day readmission risk prediction models. *PLoS One.* 2020 Aug 27;15(8):e0238065. doi: 10.1371/journal.pone.0238065. eCollection 2020. PMID: 32853223

Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, **Marsh R**, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. *Cancer.* 2019 May 15;125(10):1629-1636. doi: 10.1002/cncr.31938. Epub 2019 Jan 15. PMID: 30645764

Siddiqui NY, **Helfand BT**, Andreev VP, Kowalski JT, Bradley MS, Lai HH, Berger MB, Mueller MG, Bickhaus JA, Packiam VT, Fenner D, Gillispie BW, Kirkali Z. Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses. *J Urol.* 2019 Nov;202(5):880-889. doi: 10.1097/JU.0000000000000257. Epub 2019 Oct 9. PMID: 30925127

Side L, Thomas T, Van Asperen C, Vassen H, Kiemeny LA, Ringelberg J, Jensen TD, Osther PJS, **Helfand BT**, et al. Interim Results from the IMPACT Study: Evidence for Prostate-Specific Antigen Screening in BRCA2 Mutation Carriers. *Eur Urol.* 2019 Dec;76(6):831-842. doi: 10.1016/j.euro.2019.08.019. Epub 2019 Sep 16. PMID: 31537406

continued >

Singhi AD, Nikiforova MN, Marsh JW, Hogg M, Lee K, Bartlett DL, Pingpank JF, Humar A, Bahary N, Dasyam AK, Brand R, Fasanella KE, McGrath K, Slika A. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. *Gut*. 2020 Jan;69(1):52-61. PMID: 30971436

Smita J, Catenacci D, Karrison T, Peterson J, Zalupski M, Sehdev A, Wade J, Sadiq A, Picozzi V, Amico A, Marsh R, Kozloff M, Polite B, Kindler H, Sharma M. Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel and irinotecan (FOLFIRABRAX) in untreated gastrointestinal cancer patients using UGT1A1 genotype-guided dosing. *Clin Cancer Res*. 2020 Jan 1;26(1):18-24. doi: 10.1158/1078-0432.CCR-19-1483. Epub 2019 Sep 26. PMID: 31558477

Surman P, Razdan SN, Wang CE, Tulchinsky M, Ahmed L, Prinz RA, Winchester DJ. Thyroid Lobectomy for T1b-T2 Papillary Thyroid Cancer with High-Risk Features. *J Am Coll Surg*. 2020 Jan;230(1):136-144. doi: 10.1016/j.jamcollsurg.2019.09.021. Epub 2019 Oct 28. PMID: 31672668

Talamonti MS. Impact, Insight and Innovation: Our Legacy of Learning. *J Am Coll Surg*. 2019 Jul;229(1):1-6. doi: 10.1016/j.jamcollsurg.2019.02.041. Epub 2019 Feb 20. PMID: 30794863

Te HS, Renz J, Fimmel C. Involvement of Portal Hypertensive Gastric and Duodenal Polyps Following Liver Transplantation. *Clin Gastroenterol Hepatol*. 2019 Jun;17(7):e77-e78. doi: 10.1016/j.cgh.2018.06.007. Epub 2018 Aug 3. PMID: 30081011

Thepatee T, Shanes E, Maurer D, Palma E, Lee H-K, Benirschke R, Dohnal J, Pease G, Walls T, Thomson R Jr, Kaul K. A New Era in Pathology Consultation: The MyPathologist Electronic Consultation Tool. *Acad Pathol*. 2018 Sep 10;5:2374289518798820. doi: 10.1177/2374289518798820. eCollection Jan-Dec 2018. PMID: 30214917

Thoracic Surgery Outcomes Research Network, Inc, Antonoff M, Backhus L, Krantz S, Wood DE. COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement from Thoracic Surgery Outcomes Research Network. *Ann Thorac Surg*. 2020 Aug;110(2):692-696. doi: 10.1016/j.athoracsurg.2020.03.005. Epub 2020 Apr 9. PMID: 32278755

Thoracic Surgery Outcomes Research Network, Inc, Antonoff M, Backhus L, Krantz S, Wood DE. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. *J Thorac Cardiovasc Surg*. 2020 Aug;160(2):601-605. doi: 10.1016/j.jtcvs.2020.03.061. Epub 2020 Apr 9. PMID: 32689703

Vickman RE, Broman MM, Lanman NA, Franco OE, Sudyanti PAG, Ni Y, Ji Y, Helfand BT, Petkewicz J, Paterakos MC, Crawford SE, Ratliff TL, Hayward SW. Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. *Prostate*. 2020 Feb;80(2):173-185. doi: 10.1002/pros.23929. Epub 2019 Nov 25. PMID: 31763714

Vickman RE, Faget DV, Zheng Y, Hayward SW, Stewart SA. Deconstructing Tumor Heterogeneity: The Stromal Perspective. *Oncotarget*. 2020 Oct 6, (in press):11(40):3621-3632. doi: 10.18632/oncotarget.27736. PMID: 33088423

Vickman RE, Franco OE, Hayward SW. Contributions of Carcinoma-Associated Fibroblasts to the Prostate Cancer Microenvironment. *Curr Opin in Endo. and Metabol. Res*. 10, 1-6

Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumvikat P, Hayward SW. The Role of the Androgen Receptor in Prostate Development and Benign Prostatic Hyperplasia. *Asian J Urol*. 2020 Jul;7(3):191-202. doi: 10.1016/j.ajur.2019.10.003. Epub 2019 Oct 19. PMID: 32742923

Victorson D, Schalek BD, Kundu S, Helfand BT, Novakovic K, Penedo F, Cella D. Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety. *Cancer*. 2019 Sep 15;125(18):3249-3258. doi: 10.1002/cncr.32189. Epub 2019 May 15. PMID: 31090933

Victorson D, McMahon M, Horowitz B, Glickson S, Parker B, Mendoza Temple L. Exploring cancer survivors' attitudes, perceptions and concerns about using medical cannabis for symptom and side effect management: A qualitative focus group study. *Complement Ther Med*. 2019 Dec;47:102204. doi: 10.1016/j.ctim.2019.102204. Epub 2019 Oct 10. PMID: 31779995

Vining CC, Eng OS, Hogg ME, Schultevoerder D, Silverman RS, Yao KA, Winchester DJ, Roggin KK, Talamonti MS, Posner MC, Turaga KK, Tseng J. Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future. *Ann Surg Oncol*. 2020 May 18:1-5. doi: 10.1245/s10434-020-08623-2. Online ahead of print. PMID: 32424589

Vining CC, Hogg ME. How to train and evaluate minimally invasive pancreas surgery. *J Surg Oncol*. 2020 Jul;122(1):41-48 (Review). doi: 10.1002/jso.25912. Epub 2020 Mar 25. PMID: 32215926

Vining CC, Kuchta K, Schultevoerder D, Paterakos P, Berger Y, Roggin KK, Talamonti MS, Hogg ME. Risk factors for complications in patients undergoing pancreaticoduodenectomy: A NSQIP analysis with propensity score matching. *J Surg Oncol*. 2020 Aug;122(2):183-194. doi: 10.1002/jso.25942. Epub 2020 May 23. PMID: 32445612

Wake DT, Ilbawi N, Dunnenberger HM, Hulick PJ. Pharmacogenomics: Prescribing Precisely. *Med Clin North Am*. 2019 Nov;103(6):977-990. doi: 10.1016/j.mcna.2019.07.002. Epub 2019 Aug 24. PMID: 31582008

Wang J, Sun J, Hu J, Wang C, Prinz RA, Peng D, Liu X, Xu X. A771726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. *FASEB J*. 2020 Jun 29. doi: 10.1096/fj.201902793RR. Online ahead of print. PMID: 32598086

Weiner R, Hanson B, Rehman J, Sun B. Isolated testicular vasculitis due to immune checkpoint inhibitor. *Eur J Rheumatol*. 2019 Nov 25;7(1):35-36. doi: 10.5152/eurjrh.2019.19061. Print 2020 Jan. PMID: 31782719

West (DePersia) AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghani A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. *Cancer Med*. 2019 Sep;8(12):5609-5618. doi: 10.1002/cam4.2471. Epub 2019 Aug 12. PMID: 31407530

Wong AK, Raviv J, Ciric I, Wong RH. Novel Use of Bio-Dissolvable Stent in the Treatment of Recurrent Rathke's Cleft Cyst. *World Neurosurg*. 2019 Nov; 131:186-190. PMID: 31421294

Wong AK, Raviv J, Wong RH. Sellar trough technique for endoscopic endonasal transsellar repair. *Surg. Neurol. Int*. 2020 May; 11:99. PMID: 32494378

Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, Gietzak M, Na R, Sarver BAJ, Helfand BT, Walsh PC, Lotan TL, Cooney KA, Black MH, Xu J, Isaacs WB. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. *Eur Urol Oncol*. 2020 Apr;3(2):224-230. doi: 10.1016/j.euo.2019.12.003. Epub 2020 Jan 14. PMID: 31948886

Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, Carter HB, Cooney KA, Isaacs WB, Xu J. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. *Prostate*. 2018 Jun;78(8):607-615. doi: 10.1002/pros.23505. Epub 2018 Mar 9. PMID: 29520813

Xu J, Labbate CV, Isaacs WB, Helfand BT. Inherited risk assessment of prostate cancer: it takes three to do it right. *Prostate Cancer Prostatic Dis*. 2020 Mar;23(1):59-61. doi: 10.1038/s41391-019-0165-y. Epub 2019 Aug 15. PMID: 31417171

Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang E, Saha P, Gulukota K, Helseth DL Jr, Guise T, Prabhakar BS, Kaul K, Schreiber H, Seth P. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. *Hum Gene Ther*. 2020 Aug;31(15-16):863-880. doi: 10.1089/hum.2020.078. Epub 2020 Jun 12. PMID: 32394753

Yan H, Calcaterra N, Moo-Young TA, Prinz RA, Winchester DJ. Degree of hypercalcemia correlates with parathyroidectomy but not with symptoms. *Am J Surg*. 2019 Mar;217(3):437-440. doi: 10.1016/j.amjsurg.2018.09.010. Epub 2018 Sep 21. PMID: 30262120

Yan H, Hunter E, Akoulitchev A, Park P, Winchester DJ, Moo-Young TA, Prinz RA. Epigenetic chromatin conformation changes in peripheral blood can detect thyroid cancer. *Surgery*. 2019 Jan;165(1):44-49. doi: 10.1016/j.surg.2018.05.081. Epub 2018 Oct 28. PMID: 30377001

Yang Y, Xu W, Peng D, Wang H, Zhang X, Wang H, Xiao F, Zhu Y, Ji Y, Gulukota K, Helseth DL Jr, Mangold KA, Sullivan M, Kaul K, Wang E, Prabhakar BS, Li J, Wu X, Wang L, Seth P. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy. *Hum Gene Ther*. 2019 Sep;30(9):1117-1132. doi: 10.1089/hum.2019.059. Epub 2019 Jul 1. PMID: 31126191

Yao K, Belkora J, Lee C, Kuchta K, Pesce C, Kopkash K, Rabbitt S, Barrera E, Simovic S, Sepucha K. An In-Visit Decision Aid for Surgeons to Address Decision Making for Bilateral Mastectomy for Newly Diagnosed Breast Cancer Patients. *Ann Surg Oncol*. 2019 Dec;26(13):4372-4380. doi: 10.1245/s10434-019-07912-9. Epub 2019 Oct 17. PMID: 31625046

Yao K, Bleicher R, Moran M, Chang C, Dietz J, Stearns V, Connolly J, Sarantou R, Kurtzman S. Differences in Physician Opinions About Controversial Issues Surrounding Contralateral Prophylactic Mastectomy (CPM): A Survey of Physicians from Accredited Breast Centers in the United States. *Cancer Med*. 2020 May;9(9):3088-3096. doi: 10.1002/cam4.2914. Epub 2020 Mar 11. PMID: 32159280

Yu H, Shi Z, Lin X, Bao Q, Jia H, Wei J, Helfand BT, Zheng SL, Duggan D, Lu D, Mo Z, Xu J. Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment. *Prostate*. 2020 Jan;80(1):83-87. doi: 10.1002/pros.23920. Epub 2019 Oct 21. PMID: 31634418

Yu H, Shi Z, Wu Y, Wang CH, Lin X, Perschon C, Isaacs WB, Helfand BT, Lilly Zheng S, Duggan D, Mo Z, Lu D, Xu J. Concept and benchmarks for assessing narrow-sense validity of genetic risk score values. *Prostate*. 2019 Jul;79(10):1099-1105. doi: 10.1002/pros.23821. Epub 2019 Apr 29. PMID: 31037745

Zeh H, Bahary N, Boone BA, Singhi AD, Miller-Ocun JL, Normolle DP, Zureikat AH, Hogg ME, Bartlett DL, Lee KK, Tsung A, Marsh JW, Murphy P, Tang D, Seiser N, Amaravadi RK, Espina V, Liotta L, Lotze MT. A Randomized Phase II Preoperative Study of Autophagy Inhibition With High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. *Clin Cancer Res*. 2020 Mar 10. pii: clincanres.4042.2019. doi: 10.1158/1078-0432.CCR-19-4042. [Epub ahead of print] PMID: 32156749

Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Hulick PJ, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nat Genet*. 2020 Jun;52(6):572-581. doi: 10.1038/s41588-020-0609-2. Epub 2020 May 18. PMID: 32424353

Zhang J, Ruan T, Sheng T, Wang J, Sun J, Wang J, Prinz RA, Peng D, Liu X, Xu X. Role of c-Jun terminal kinase (JNK) activation in influenza A virus-induced autophagy and replication. *Virology*. 2019 Jan 2;526:1-12. doi: 10.1016/j.virol.2018.09.020. Epub 2018 Oct 10. PMID: 30316042

Zhao H, Wang H, Kong F, Xu W, Wang T, Xiao F, Wang L, Huang D, Seth P, Yang Y, Wang H. Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model. *Hum Gene Ther*. 2019 Feb;30(2):197-210. doi: 10.1089/hum.2018.055. Epub 2018 Oct 2. PMID: 30032645

Zureikat AH, Beane JD, Zenati MS, Al Abbas AI, Boone BA, Moser AJ, Bartlett DL, Hogg ME, Zeh HJ 3rd. Pancreatoduodenectomies: One Decade of Optimizing Performance. *Ann Surg*. 2019 Dec 4. doi: 10.1097/sla.0000000000003550. PMID: 31851003

Zwart MJW, Jones LR, Balducci A, Takagi K, Vanlander A, van den Boezem PB, Daams F, Rosman C, Lips DJ, Moser AJ, Hogg ME, Busch ORC, Stommel MWJ, Besselink MG. Dutch Pancreatic Cancer Group. Added value of 3D-vision during robotic pancreatoduodenectomy anastomoses in biotissue (LAEBOT 3D2D): A randomized controlled cross-over trial. *Surg Endosc*. 2020 Jul 12. doi: 10.1007/s00464-020-07732-z. PMID: 32661707

Academic Leadership Roles and Awards 2019–2020

Kellogg Cancer Center physicians are active in a broad range of regional and national organizations.

Bruce Brockstein, MD

- Member, Head and Neck Committee, Eastern Cooperative Oncology Group, 2000-present
- *Chicago* magazine Top Doctors, 2006, 2008, 2010, 2012, 2014, 2016

Editorial:

- Manuscript Reviewer: *Head and Neck, Annals of Surgical Oncology*
- Grant Reviewer: Cancer Research UK
- *UpToDate* (Online Textbook), Chapter Editor, Head and Neck Cancer, 2000-present

Nicholas Campbell, MD

Editorial:

- Reviewer: *Clinical Lung Cancer, Case Reports*

Claus Fimmel, MD, CPE

- Advisory Board, American Liver Foundation, Chicago Chapter, 2008-present

Editorial:

- The *Open Proteomics Journal* (ISSN 1875-0397) (2008-present)
- *Liver Cancer Review Letters* (2009-present)

David Grinblatt, MD

- Community Oncology Committee, Alliance for Clinical Trials in Oncology, 2010-present

Editorial:

- Ad Hoc Reviewer: *Annals of Oncology*, 1996-present

Brian Helfand, MD

- Principal Investigator, Prostate Cancer SPORC project concerning genetics underlying active surveillance failures
- Visiting Professorships in Shanghai, China
- Member, Bladder Cancer Consortium and Guideline Committee
- Member, Relative Value Scale Update Committee (RUC)
- 45 peer-reviewed publications this year

Thomas Hensing, MD, MS

- Respiratory Health Association, Lung Cancer Initiative Advisory Council, 2005-present
- Alliance for Clinical Trials in Oncology, Respiratory Committee Member, 2010-present

Melissa Hogg, MD, MS

- Co-Chair of the HPB Task Force, SAGES
- Co-Chair of the HPB Disease Site Working Group, SSO
- Associate Editor, "Surgical Techniques" Division, *Journal of Surgical Oncology*
- Chair of the Training and Implementation Committee for the International Evidence-Based Consensus Guidelines of Minimally Invasive Pancreas Resections
- Founding Member of the International Consortium on Minimally Invasive Pancreatic Surgery

Karen Kaul, MD, PhD

- American Board of Pathology: Appointed Trustee, 2011-present; ACGME Residency Program Review Committee, 2012-present; Secretary, Executive Committee, 2015-present; Communications Task Force, 2012-present; Chair, Test Development & Advisory Committee for Molecular Genetics, 2012-present; Vice President, Executive Committee, 2017; President, Executive Committee, 2018; ABP/PROD Entrustable Professional Activities Task Force, 2017; Maintenance of Certificate Committee, 2012-present; Credentials Committee, 2012-present; ACGME Milestones 2 Committee, 2018-present
- College of American Pathologists, Member, Executive Advisory Board, *Archives of Pathology & Laboratory Medicine*, 2015-present
- PRODS (Pathology Residency Program Directors), Member PRODS Council, 2009-present; Council of Medical Specialty Societies/OPDA representative, 2009-present; Training Residents in Genomics (TRIG) Joint Committee, 2010-present
- Association of Pathology Chairs, Member, 2012-present; elected Chair, GME Committee, 2015-2018; Executive Council, 2015-present
- Ad Hoc Member, NIH/NCI P01 reviewer, 2001-present
- SBIR Review Panels, various (Panel Chairperson, 2010-present), 2008-present
- Peer Reviewer, Prostate Cancer Foundation, 2010-present
- Peer Reviewer, University of Chicago CTSA Pilot Program, 2011-present
- Chair, NorthShore Auxiliary Breast/Ovarian Research Program, 2013-present

Editorial Activities:

- Editorial Board, *Annual Review of Pathology*, 2011-present
- Associate Editor, *Academic Pathology*, 2014-present
- Executive Advisory Board, *Archives of Pathology & Laboratory Medicine*, 2015-present
- Ad Hoc Reviewer: *Cell Growth and Differentiation, Pediatric Pathology, Cancer, Clinical Microbiology Reviews, Tubercle, Chest, Archives of Pathology & Laboratory Medicine, Clinical Chemistry, American Journal of Clinical Pathology*, 1990-present

Janardan Khandekar, MD

Editorial:

- Reviewer: *JAMA Oncology, Journal of National Cancer Institute*
- Associate Editor, *Journal of Surgical Oncology*

Katherine Kopkash, MD

- Oncoplastic Surgery Committee for the American Society of Breast Surgeons
- Chair of Oncoplastic Breast Surgery for Beginners Curriculum Committee, American Society of Breast Surgeons
- Chicago Surgical Society Young Surgeons Committee

Seth Krantz, MD

- Invited Question Writer, Self-Education Self-Assessment in Thoracic Surgery (SESATS) XIII (13), American Board of Thoracic Surgery

Editorial:

- Reviewer: *Chest, American Journal of Clinical Oncology*, 2016-present; *Annals of Thoracic Surgery*, 2015-present; *Journal of Thoracic and Cardiovascular Surgery*, 2014-present; *Annals of Surgical Oncology*, 2011-present

Robert Marsh, MD

- Eastern Cooperative Oncology Group, GI Committee

Editorial Work:

- *American Journal of Clinical Oncology, British Medical Journal, Cancer, Cancer Management and Research, Cell, European Journal of Surgical Oncology, Journal of Cancer Research and Clinical Oncology, Journal of Surgical Oncology, Journal of the Pancreas, Lancet Oncology, Public Library of Science, Rogers Medical Intelligence Solutions CME Programs, Southern Medical Journal, Therapeutic Advances in Gastroenterology*

Leslie Mendoza Temple

- Guest Editor, Complementary Therapies in Medicine special issue of *Medical Cannabis*, for 2021 publication

Catherine Pesce, MD

- Young Surgeons Committee of the Chicago Surgical Society

Richard Prinz, MD

- Editorial Review Board: *Surgery, Langenbeck's Archives of Surgery*

Gustavo Rodriguez, MD

- Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group/NRG, 1997-present
- Advisory Board, Gilda's Club, Chicago, IL, 2004-present

Carol Rosenberg, MD

- Chair of 2018 Cancer Survivorship Symposium, ASCO-ACP-AAFP Advancing Care and Research—A Primary Care and Oncology Collaboration
- Patient-Centered Outcomes Research Initiative (PCORI) National Comparative Effectiveness Evaluation of Survivorship Programs in the United States. LIFE Site Project Supervisor—LIFE Program Participant Program
- Research Investigator, Women's Health Initiative study, National Institutes of Health (NIH), 1999-present

Awards:

- Myra Rubenstein Weis LIFE Program Grant Award Recipient: Myra Rubenstein Weis Health Resource Center Foundation, NorthShore University HealthSystem, May 2019

Prem Seth, PhD

- Editorial Board, *Cancer Gene Therapy*
- Editorial Board, *Molecular Therapy—Oncolytics*

Daniel Shevrin, MD

- Director, Advocacy Core Prostate SPORE, Northwestern University, 2003-present
- Medical Director, NorthShore Chapter of US TOO Prostate Cancer Support Group, 2002-present
- Board Member, Cancer Wellness Center, Northbrook, IL, 2010-present
- Member, National Cancer Institute (NCI) GU Steering Committee, 2014-2017

Mark Sisco, MD, FACS

- Program Committee, Breast Subsection, American Society of Plastic Surgeons, 2015-present
- In-Service Examination Committee, American Society of Plastic Surgeons, 2016-present

Editorial:

- Editorial Board Member and Peer Reviewer, *Microsurgery*, 2017
- Peer Reviewer, *Cancer Control*, 2017
- Editorial Board Member and Peer Reviewer, *Journal of Surgical Oncology*, 2014-present
- Peer Reviewer, *Journal of Surgical Research*, 2010-present

Norman Smith, MD

- Member, American Urological Association Relative Value Scale Update Committee (RUC) (2016-present); Coding and Reimbursement Committee (2016-present); Public Policy Council (2015-present)
- Vice Chair, AMA/Specialty Society Relative Value Scale Update Committee (RUC) Relativity Assessment Workgroup (2019-present)
- Secretary/Treasurer and Executive Committee of Chicago Urological Society

Mark Talamonti, MD

- Society of Surgical Oncology, Foundation Board of Directors, 2014-2019; Chairman, Corporate Relations Committee, 2017-2019; Chairman, Local Arrangements Committee, 2017-2018
- Western Surgical Association, Membership Committee, 2012-present; Treasurer, 2012-present, Elected President, 2017-2018
- Americas Hepato-Pancreato-Biliary Association, 2018-2020; Finance Committee, 2019-2021; AHPBA Member at Large—Executive Council

Editorial:

- Editorial Board: *Annals of Surgical Oncology*, *Journal of Surgical Oncology* (Section Editor, *Hepatobiliary and Pancreas*)
- Invited Reviewer: *American Journal of Surgery*, *Annals of Surgery*, *Archives of Surgery*, *Cancer*, *Journal of the American College of Surgeons*, *Journal of Clinical Oncology*, *Oncology*, *Surgery*, *World Journal of Surgery*

Awards:

- Outstanding Faculty Teacher Award, Department of Surgery, University of Chicago Pritzker School of Medicine, 2017 and 2018
- Castle Connelly and *Chicago* magazine, Top Doctors in America and Chicago, 1995-2018
- *U.S. News & World Report*, Top 1% of Surgeons in America, 2007-2018

Lauren Wiebe, MD

- Palliative Care Research Cooperative Group, NorthShore Site Organizational Lead, 2017-present
- Palliative Care Research Cooperative Group, Scientific Review Committee Member, 2016-2019

- Palliative Care Research Cooperative Group, Junior Investigator, 2014-present
- Coleman Supportive Oncology Collaborative, Advanced Disease Team, Member, 2016-2018
- 2019 Special Guest Speaker at the PanCAN PurpleStride, June 29, 2019, Soldier Field, Chicago, IL

Editorial:

- Invited Peer Reviewer, *Journal of Oncology Practice*

Awards:

- Coleman Foundation Grant, 2019-2020

David J. Winchester, MD

- Director, Rice Foundation, 1998-present
- American Joint Committee on Cancer (AJCC), 2004-present; Vice-Chairman, 2011-present; Committee, 2008-present; Education and Promotions Committee, 2007-present
- Member, Alliance ACS Clinical Research Program, 2012-present

Editorial:

- Member of Editorial Board, *American Journal of Clinical Oncology*, 2006-present; Associate Editor, 2009-present
- Member of Editorial Advisory Board, *American Family Physician*, 2012-present
- Member of Editorial Board, *Journal of Surgical Oncology*, 2015-present
- Ad Hoc Reviewer: *Annals of Surgical Oncology*, *British Journal of Cancer*, *Cancer*, *Canadian Medical Association Journal*, *Clinical Breast Cancer*, *Cancer Control: Journal of the Moffitt Cancer Center*, *Journal of Clinical Oncology*, *The Lancet Oncology*, *World Journal of Surgical Oncology*

Katharine Yao, MD

- Member, Patient-Reported Outcomes Working Group, American Society of Breast Surgeons
- Member, Publications Committee, American Society of Breast Surgeons
- Member, Practice Advocacy Committee, American Society of Breast Surgeons
- Alliance for Clinical Trials, Prevention Committee, Women's Cancer Working Group Chair
- Vice Chair, National Accreditation Program for Breast Centers
- American College of Radiology, Supplemental Screening for Breast Density, Appropriateness Criteria Breast Imaging Committee
- President-Elect, Chicago Surgical Society
- Dudley P. Allen Visiting Professor at University Hospitals Cleveland Medical Center, September 25, 2019

Editorial Boards:

- *Surgical Oncology*, 2017-2018
- *Annals of Surgery*, 2017-2018

Grant Awards:

- Patient Values in Surgical Decision Making for Breast Cancer Surgery. John Wayne Cancer Foundation Grant. Award Recipient, PI: Yao, K. 5/2018-6/2019
- Implementing and Disseminating Risk-Stratified Screening for Breast Cancer at NorthShore. Phase I: Identification of High-Risk Women (The IDENTIFY Study), Breast and Ovarian Research Pilot, NorthShore University HealthSystem, Principal Investigator: Yao, K. 5/2019-6/2020
- Invited speaker: Dutch Breast Cancer Conference, Bossche Mamma Congress, June 18-19, 2019

Locations

Evanston Breast Center (EVB)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Hospital (EH)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Kellogg Cancer Center (EVK)

2650 Ridge Avenue, Evanston, IL 60201

Evanston Specialty Suites (EV)

1000 Central Street, Evanston, IL 60201

Glenbrook Breast Center (GBB)

2050 Pfingsten Road, Suite 130
Glenview, IL 60026

Glenbrook Hospital (GBH)

2100 Pfingsten Road, Glenview, IL 60026

Glenbrook John and Carol Walter Ambulatory Care Center (GB)

2180 Pfingsten Road, Glenview, IL 60026

Glenbrook Kellogg Cancer Center (GBK)

2180 Pfingsten Road, Suite 1000
Glenview, IL 60026

Glenbrook Medical Building (GBM)

2050 Pfingsten Road, Suite 128
Glenview, IL 60026

Glenview Park Center (GP)

2400 Chestnut Avenue, Glenview, IL 60026

Gurnee Ambulatory Care Center (GR)

7900 Rollins Road, Gurnee, IL 60031

Highland Park Ambulatory Care Center (HPS)

757 Park Avenue West, Highland Park, IL 60035

Highland Park Breast Center (HPB)

777 Park Avenue West, Suite B400
Highland Park, IL 60035

Highland Park Hospital (HPH)

777 Park Avenue West, Room 1260
Highland Park, IL 60035

Highland Park Kellogg Cancer Center (HPK)—Ellen Marks Ambulatory Care Center

757 Park Avenue West, Suite 1810
Highland Park, IL 60035

Highland Park Medical Building (HP)

767 Park Avenue West, Suite B100
Highland Park, IL 60035

Lake Bluff Medical Building (LB)

71 Waukegan Road, Suite 700
Lake Bluff, IL 60044

Mount Prospect Medical Building (MP)

1329 Wolf Road, Mount Prospect, IL 60056

Northbrook Medical Building (NMB)

501 Skokie Boulevard, Northbrook, IL 60062

NorthShore Medical Group (SKM)—Skokie

9933 Woods Drive, Suite 200, Skokie, IL 60077

Skokie Ambulatory Care Center (SK)

9650 Gross Point Road, Suite 3000
Skokie, IL 60076

Swedish Hospital (SW)

5140 N. California Avenue
Chicago, IL 60625

Vernon Hills Specialty Suites (VH)

225 North Milwaukee Avenue
Vernon Hills, IL 60061

Physician Directory



Matthew Adess, MD
Medical Director, Highland Park Kellogg Cancer Center
Expertise: GI Oncology; Benign and Malignant Hematology
Locations: GBK, GR, HPK



Marc Alonzo, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Thomas Aquisto, MD
Director, Interventional Radiology
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Hassan Arshad, MD
Director, Head and Neck Surgery
Expertise: Head and Neck Cancers; Thyroid and Parathyroid Surgery; Robotic Surgery
Location: EVK



Julian Bailes, MD
Chair, Department of Neurosurgery
Co-Director, NorthShore Neurological Institute
Expertise: Brain and Spine Tumor Surgery
Locations: EV, HPS, SW



William Bloomer, MD
Chair, Department of Radiation Oncology
Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer
Locations: EH, HP



Michael Blum, MD
Expertise: Urologic Oncology
Locations: EV, HPS



Bruce Brockstein, MD
Division Head, Hematology/Oncology
Medical Director, Kellogg Cancer Center
Expertise: Head and Neck Cancers; Melanoma; Sarcoma
Locations: EVK, HPK



Elizabeth Burke, MD
Expertise: Breast Reconstruction; Microsurgery; Melanoma; Facial Reconstructive Surgery
Location: NMB



Nicholas Campbell, MD
Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers
Locations: EVK, HPK



Shakeel Chowdhry, MD
Expertise: Brain and Spine Tumor Surgery; Stereotactic Radiosurgery
Locations: EV, GB



Jeffrey Cilley, MD
Vice President, Swedish Hospital
Oncology
Expertise: Oncology and Hematology
Location: SW



Peter Colegrove, MD
Expertise: Urologic Oncology
Locations: EV, GB



Allison DePersia, MD
Expertise: High Risk Breast, Hereditary Cancer
Location: EV



Thomas Farrell, MD
Section Chief, Interventional Radiology
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK



Claus Fimmel, MD
Expertise: Liver Diseases; Gastrointestinal Diseases; GI Endoscopy; Liver Biopsy
Locations: EV, HPS, SK



Alla Gimelfarb, MD
Medical Director, Kellogg Cancer Center Immediate Care
Expertise: Benign and Malignant Hematology
Location: GBK



David Grinblatt, MD
Expertise: Benign and Malignant Hematology
Locations: EVK, GBK



Britt Hanson, DO
Expertise: Melanoma; Benign and Malignant Hematology
Locations: GR, HPK



Brian Helfand, MD, PhD
Division Head, Urology
Expertise: Prostate Cancer
Location: GB



Thomas Hensing, MD, MS
Co-Director of the Thoracic Oncology Program, Associate Chief Quality Officer for Ambulatory Care, Deputy Division Head, Hematology Oncology
Expertise: Lung Cancer; Esophageal Cancer
Locations: EVK, GBK



Melissa Hogg, MD, MS
Director, Liver and Pancreas Surgery
Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Primary and Metabolic Liver Tumors; Neuroendocrine Tumors; Sarcoma
Locations: EVK, GBM



Peter Hulick, MD, MMSc
Division Head, Medical Genetics
Director, Center for Personalized Medicine
Expertise: Medical Genetics
Locations: EV, HPK



Javed Imam, MD
Expertise: Oncology
Location: SW



Mary Tilley Jenkins Vogel, MD
Expertise: Gynecologic Oncology
Locations: EVK, GBK, SW



Lynne Kaminer, MD
Section Chief, Hematology
Expertise: Benign and Malignant Hematology
Locations: EVK, GBK



Eileen Kelly, MD
Expertise: Cardio-Oncology; Clinical Cardiology
Location: GB



Janardan Khandekar, MD
Director, Center for Molecular Medicine
Expertise: Endocrine; Breast Cancer
Location: EVK



Carolyn Kirschner, MD
Expertise: Gynecologic Oncology; Cancer Survivorship
Locations: EVK, GBK



Madhuri Konanahalli, MD
Expertise: Skin Cancer; General Dermatology
Location: EV

Physician Directory *(continued)*



Katherine Kopkash, MD
Expertise: Breast Cancer;
Oncoplastic Breast Surgery; Breast
Health; Breast Disease and Surgery
Locations: EVB, GBB



Andrew Melnyk, MD
Expertise: Medical Genetics
Location: EV



Sangtae Park, MD, MPH
Expertise: Prostate Cancer;
Urologic Oncology
Locations: EV, GB



Seth Krantz, MD
Expertise: Lung Cancer;
Esophageal Cancer; Minimally
Invasive Thoracic Surgery
Locations: EVK, HPK, GBK



Gregg Menaker, MD
Expertise: Mohs Surgery;
Dermatologic Surgery; Laser Surgery
Location: SKM



Rupa Patil, MD
Expertise: Cardio-Oncology;
Clinical Cardiology
Locations: EV, VH



Monika Krezalek, MD
Expertise: Minimally Invasive
Colon and Rectal Surgery; Colon
and Rectal Cancer; Inflammatory
Bowel Disease; Anorectal Surgery;
Colonoscopy
Locations: EV, GB, HPS



Douglas Merkel, MD
Expertise: Breast Cancer
Locations: EVK, GBK, HPK



Catherine Pesce, MD
Director, Surgical Breast Program
Expertise: Breast Cancer; Breast
Health; Breast Disease and
Surgery
Locations: HPB, HPK



Elyse Lambiase, MD
Expertise: Oncology and
Hematology
Location: SW



Ryan Merrell, MD
Program Director, Neuro-Oncology
Expertise: Brain Cancer; Brain
Tumor; Neurologic Complications
of Cancer; Tumor in the Central
Nervous System (Brain or Spine)
Locations: EVK, GB, GBK, SW



Nicklas Pfanztel, MD
Expertise: Genitourinary Cancer;
Lung Cancer
Locations: EV, GBK, HPK



Teresa Murray Law, MD
Expertise: Breast Cancer; Prostate
Cancer; Genitourinary Cancer
Locations: EVK, HPK



Tricia Moo-Young, MD
Expertise: Minimally Invasive
Approaches to Endocrine Disorders;
Thyroid and Parathyroid Surgery;
Adrenal Disorders; Pancreatic
Exocrine; General Surgery
Locations: HPS, VH



Ariel Polish, MD
Expertise: GI Oncology; Benign
and Malignant Hematology;
Genitourinary Cancer; Lung
Cancer
Locations: EVK, GBK, GR



Ross Levy, MD
Expertise: Mohs Surgery;
Dermatologic Surgery; Laser Surgery
Location: SKM



Elena Moore, MD
Expertise: Gynecologic Oncology
Locations: EVK, HPK



Richard Prinz, MD
*Vice Chair, Administration & Clinical
Development, Department of Surgery*
Expertise: Endocrine Surgery with
Emphasis on Thyroid, Parathyroid,
Adrenal and Pancreatic
Neuroendocrine Surgery
Locations: EV, HPS, MP



John Linn, MD
*Vice Chair for Surgery,
Glenbrook Hospital*
Expertise: Gastrointestinal Surgical
Oncology Including Stomach and
Esophagus; General Surgery
Locations: EV, GBM



Joseph Muldoon, MD
Expertise: Minimally Invasive Colon
and Rectal Surgery; Colon and
Rectal Cancer; Inflammatory Bowel
Disease; General Surgery
Locations: EV, GBK, GBM



Amit Pursnani, MD
Expertise: Cardio-Oncology;
Clinical Cardiology
Locations: EV, SK



Melissa Hachen Lippitt, MD, MPH
Expertise: Gynecologic Oncology
Locations: EVK, GBK, HPK



Ranjeev Nanda, MD
Expertise: Stereotactic
Radiosurgery; Brain Tumors;
Head and Neck Cancers
Locations: EH, GBH



Vathsala Raghavan, MD
Expertise: Breast Cancer;
Gynecologic Oncology;
Head and Neck Cancers;
Thyroid Cancer
Locations: GBH, HPH



Luzheng Liu, MD
Expertise: General Dermatology;
Skin Cancers
Location: LB



Kristian Novakovic, MD
Expertise: Kidney Cancer; Prostate
Cancer
Locations: EV, GB




Joseph Raviv, MD
Expertise: Endoscopic Sinus and
Anterior Skull Base Surgery
Locations: EV, NMB



Robert Marsh, MD
Section Chief, GI Oncology
Expertise: GI Oncology
Locations: EVK, GBK



Bernhard Ortel, MD
Division Head, Dermatology
Expertise: Skin Cancer; General
Dermatology; Psoriasis; Blistering
Diseases
Location: SKM



Erwin Robin, MD
Expertise: Benign and Malignant
Hematology
Locations: GB, HP



Jason Robin, MD
Expertise: Cardio-Oncology;
Clinical Cardiology
Location: GB



Gustavo Rodriguez, MD
Division Head,
Gynecologic Oncology
Expertise: Gynecologic Oncology
Locations: EVK, HPK



Carol Rosenberg, MD
Director, Preventive Health Initiatives;
Director, Myra Rubenstein Weis
Living in the Future (LIFE) Cancer
Survivorship Program
Expertise: Cancer Survivorship
Location: HPH



Poornima Saha, MD
Expertise: Breast Cancer
Locations: EVK, GB



Akhil Seth, MD
Expertise: Breast Reconstruction;
Aesthetic Breast and Body Surgery;
Oncologic and Complex Wound
Reconstruction
Location: NMB



Arif Shaikh, MD
Expertise: Stereotactic Radiosurgery;
Head and Neck Cancers; Lung
Cancer; Gynecologic and Breast
Tumors
Locations: EH, GBH



Daniel Shevrin, MD
Medical Director,
Glenbrook Kellogg Cancer Center
Expertise: Prostate Cancer;
Genitourinary Cancer
Locations: EVK, GBK



Mark Sisco, MD
Division Head, Plastic and
Reconstructive Surgery
Expertise: Plastic Surgery;
Breast Reconstruction
Location: NMB



Norm Smith, MD
Expertise: Bladder Cancer;
Testicular Cancer; Kidney Cancer;
Advanced Urologic Cancers
Locations: EV, GB



James Spitz, MD
Expertise: Colon and Rectal Surgery;
Colonoscopy; General Surgery
Locations: GBM, HP, VH



Auddie Sweis, MD
Expertise: Endoscopic Sinus and
Anterior Skull Base Surgery
Locations: SK, LB



Mark Talamonti, MD
Department Chair, Surgery
Expertise: Gastrointestinal Surgical
Oncology; Pancreatic Cancer;
Benign and Malignant Liver Tumors;
Neuroendocrine Tumors
Location: EVK



Leslie Mendoza Temple, MD
Integrative Medicine Medical Director
Expertise: Integrative Medicine
Location: GP



Michael Ujiki, MD
Division Head, Gastrointestinal
& General Surgery
Expertise: Gastrointestinal Surgical
Oncology Including Stomach and
Esophagus; Minimally Invasive
Endoscopic Surgery; General Surgery
Locations: EV, GBM



Elaine Lee Wade, MD
Expertise: Breast Cancer;
Benign Hematology
Location: GBK



Jason Waldinger, MD
Expertise: Skin Cancer; General
Dermatology; Laser Procedures
Location: LB



Lauren Wiebe, MD
Expertise: Palliative Medicine;
GI Oncology
Locations: EH, EHK, GBK



David J. Winchester, MD
Associate Director for Surgical
Specialties, Kellogg Cancer Center
Expertise: Surgical Oncology with
Emphasis on Breast, Endocrine,
Melanoma and Sarcoma
Locations: EV, EVB, GB, GBM



Ricky Wong, MD
Expertise: Brain, Skull and
Pituitary Tumors
Locations: EV, GB



Katharine Yao, MD
Division Head, Surgical Oncology
Expertise: Breast Cancer; Breast
Health; Breast Disease and Surgery
Locations: EVB, EVK

Cancer Conferences

Breast Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Mondays, 7:30 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Colorectal Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Fridays, 7 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Genitourinary Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Fridays, 7 a.m.
NorthShore Glenbrook Hospital Videocast

Gynecology Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Thursdays, 7 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Head and Neck Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Thursdays, 8 a.m.

Hematology/Pathology Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, 8 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Hepatic Biliary Pancreatic Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, 7 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Molecular Oncology Conferences

NorthShore Evanston Hospital
Kellogg Room 4818, 1st Friday, 7 a.m.

Neuro-Oncology Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Wednesdays, 7:30 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Sarcoma/Melanoma Conferences

NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Wednesdays, 8 a.m.
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Thoracic Cancer Conferences

NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, noon
NorthShore Glenbrook and Highland Park
Hospitals Videocast

Evanston Hospital
2650 Ridge Avenue
Evanston, Illinois 60201
(847) 570-2000

Glenbrook Hospital
2100 Pfingsten Road
Glenview, Illinois 60026
(847) 657-5800

Highland Park Hospital
777 Park Avenue West
Highland Park, Illinois 60035
(847) 432-8000

Skokie Hospital
9600 Gross Point Road
Skokie, Illinois 60076
(847) 677-9600

Swedish Hospital
5140 N. California Avenue
Chicago, IL 60625
(773) 878-8200

Medical Group
1301 Central Street
Evanston, Illinois 60201
(847) 570-5235

Foundation
1033 University Place, Suite 450
Evanston, Illinois 60201
(224) 364-7200

Research Institute
1001 University Place
Evanston, Illinois 60201
(224) 364-7100



1301 Central Street
Evanston, Illinois 60201

northshore.org

A publication of the Office of Corporate Communications
EDITOR: Amy Ferguson, Assistant Vice President, Integrated
Marketing and Corporate Communications
PHOTOGRAPHY: Allen Bourgeois, Jon Hillenbrand
WRITER: Susan J. White

Cancer Committee 2020

Chairman

David J. Winchester, MD, FACS
Associate Director for Surgical Specialties,
Kellogg Cancer Center
NorthShore Cancer Committee Chairman
Board of Directors, David P. Winchester, MD,
Chair of Surgical Oncology

Physician Membership*

Matthew Adess, MD
Medical Director, Highland Park
Kellogg Cancer Center

Bruce Brockstein, MD
Medical Director, Kellogg Cancer Center,
Head, Division of Hematology/Oncology,
Kellogg-Scanlon Chair of Oncology

David Grinblatt, MD
Director, Oncology Research Program
Kellogg Cancer Center

Thomas Hensing, MD, MS
Co-Director, Thoracic Oncology Program
Head of Quality, Kellogg Cancer Center
Deputy Division Head,
Division of Hematology and Oncology
Medical Director, Evanston Kellogg Cancer
Center
NorthShore Cancer Committee Quality
Improvement Coordinator

Monika Krezalek, MD
GI Surgery

Elena Moore, MD
Gynecologic Oncology

Cancer Liaison Physician

Seth Krantz, MD
Thoracic Oncology

Kristian Novakovic, MD
Urologic Oncology

James Padgett, MD
Pathology

Catherine Pesce, MD
Surgical Oncology

Nick Pfanztel, MD
Clinical Research Coordinator

Vathsala Raghavan, MD
Radiation Oncology

Carol Rosenberg, MD
Director, Myra Rubenstein Weis
Living in the Future (LIFE) Cancer
Survivorship Program
Survivorship Program Coordinator

Poornima Saha, MD
Medical Oncology

Georgia Spear, MD
Diagnostic Radiology

Lauren Wiebe, MD
Palliative Care

Ancillary Membership

Jonella Black, PT, MS
Program Coordinator,
Rehab Services

George Carro, RPH, MS, BCOP
Senior Director, Oncology Pharmacy

Kim Cholewa, BSN
Oncology Nursing

Jamie Feld, RN
Cancer Committee Coordinator
Cancer Registry

Amy Ferguson
Assistant Vice President,
Integrated Marketing and
Corporate Communications

Linda Green, RN, MS, AOCNS
Director, Medical Group Operations,
Oncology Nursing
Kellogg Cancer Center

Sharon Huginnie
Senior Applications Analyst I
Epic IP/HOV Team
Health Information Technology
NorthShore University HealthSystem

Rachel Mees
Assistant Vice President,
Medical Group
Cancer Program Administrator
Kellogg Cancer Center

Sabina Omercajic, MS, CCRP
Outreach Coordinator
Kellogg Cancer Center

Anisha Patel, APN
Clinical Coordinator,
Living in the Future (LIFE)
Cancer Survivorship Program

Shayna Purcell, MS, CGC
Medical Genetics

Denise Rehberger, RN, BSN
Manager, Hospice

Jessica Smith
Cancer Control Strategic
Partnerships Manager
American Cancer Society Liaison

Irene Ziaya, LCSW
Psychosocial Services
Coordinator/Social Work

Debra Ziegler, MLIS, CTR
Quality Coordinator, Cancer Registry
NorthShore Cancer Committee
Cancer Registry Quality Coordinator
Cancer Conference Coordinator

Lisa Zoberman, RDN, LDN
Oncology Nutrition
Kellogg Cancer Center

* All academic affiliations are with the University of Chicago Pritzker School of Medicine

